Probiotic plasmids and uses thereof

Recombinant conjugative plasmids with multiple entry prevention systems inhibit the transfer of AMR and toxic plasmids, effectively protecting bacterial populations from acquiring undesirable traits, addressing the challenge of AMR spread.

JP2024541535APending Publication Date: 2024-11-08THE WESTMEAD INSTITUTE FOR MEDICAL RESEARCH +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024531426
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-25
Filing Date
2022-11-25
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

The increasing prevalence of antimicrobial resistant (AMR) bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Salmonella, poses a significant threat due to the acquisition and spread of plasmids carrying antimicrobial resistance genes (ARGs) and virulence factors, which are difficult to cure and contribute to bacterial infections.

Method used

Development of recombinant conjugative plasmids containing multiple entry prevention systems (EES) to inhibit the transfer of undesirable plasmids, specifically using probiotic plasmids with multiple variants of the IncF EES gene to prevent the acquisition of AMR and toxic plasmids in bacterial populations.

Benefits of technology

The recombinant plasmids effectively protect over 99.99% of bacterial populations from acquiring IncF plasmid variants carrying AMR, significantly reducing the spread of undesirable traits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024541535000001_ABST
    Figure 2024541535000001_ABST
Patent Text Reader

Abstract

The present disclosure generally relates to conjugative plasmids containing multiple entry-blocking systems derived from plasmids carrying genes that confer undesirable traits of interest, such as pathogenic traits, such as antimicrobial resistance (AMR), virulence determinants, metal resistance, or other undesirable traits, and the use of these probiotic plasmids to protect bacterial populations (e.g., residing in the gut, environment, etc.) from acquiring plasmids that confer undesirable traits, thereby preventing the spread of undesirable traits (e.g., AMR, virulence, or metal resistance, etc.) within the microbiota.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority from Australian Provisional Patent Application No. 2021 / 903809, filed November 25, 2021, the contents of which are incorporated herein by reference in their entirety.

[0002] Technical Field The present disclosure generally relates to conjugative plasmids containing multiple entry-blocking systems derived from plasmids carrying genes that confer undesirable traits of interest, such as pathogenic traits, such as antimicrobial resistance (AMR), virulence determinants, metal resistance, or other undesirable traits, and the use of these probiotic plasmids to protect bacterial populations (e.g., residing in the gut, environment, etc.) from acquiring plasmids that confer undesirable traits, thereby preventing the spread of undesirable traits (e.g., AMR, virulence, or metal resistance, etc.) within the microbiota. [Background technology]

[0003] Antimicrobial agents underpin many aspects of modern medicine, including treating infections, preventing infections during surgical procedures, and protecting immunocompromised patients from infection. However, over the past few decades, the use of antibiotics and other antimicrobial agents in human medicine, animal husbandry, veterinary practice, and aquaculture has increased dramatically. Despite an increasing trend in many countries toward improved antimicrobial stewardship, historically overused antimicrobial agents have been selected against many mutant strains of bacteria that are resistant to commonly used antimicrobial agents. As a result, one of the major threats facing society is the increasing number of antimicrobial resistant (AMR) bacteria, such as Escherichia coli, Klebsiella pneumoniae, and Salmonella. The ability of these bacteria to resist the effects of antibiotics is largely mediated by invasive plasmids that carry antimicrobial resistance genes (ARGs), which cannot be eliminated once acquired due to the use of a "dependency system." Similarly, virulence factors are bacteria-associated molecules necessary for bacteria to cause disease while infecting eukaryotic hosts, such as humans. A large number of virulence factors encoded by bacterial pathogens are also plasmid-derived. For example, plasmids in Salmonella, Shigella, E. coli, and Yersinia species carry virulence genes (Pilla and Tang 2018). In summary, virulence factors important for microbial pathogens, and the virulence plasmids that encode these factors, play important roles in disease. Virulence plasmids help bacteria infect humans, animals, and plants by diverse mechanisms. Some virulence factors are toxins that damage or kill animal cells, other toxins help bacteria attach to and invade animal cells, while still other virulence factors protect bacteria from the immune system.

[0004] Many pathogenic bacteria carry genes for AMR, virulence, or metal resistance on extrachromosomal mobile genetic elements such as plasmids. Large plasmids are efficiently transferred between bacteria by cell-to-cell contact (conjugation) and, once acquired, ensure their survival in bacterial populations through dependency systems. Due to their self-transmission properties, bacteria can rapidly acquire their plasmids from exposure to environments where AMR, virulence, or metal resistance is endemic or widespread, such as hospitals, clinics, contaminated sites, environments with metal toxicity, etc. Once acquired, these plasmids are unlikely to be lost or eliminated due to their dependency properties. Therefore, it is highly desirable to protect bacteria from AMR or virulence plasmid acquisition from the beginning in order to reduce the amount of virulence plasmids and control their spread.

[0005] At present, there are limited strategies to combat virulence / AMR spread. Plasmid cure (AMR plasmids are removed from the bacterial population) and anti-plasmid approaches are being explored to reduce ARG prevalence and render bacteria susceptible to antibiotics. However, at present, no plasmid cure treatment options are approved or available. In fact, very few cure mechanisms have been tested in vivo, even in experimental models. Although research efforts on plasmid cure approaches have come a long way, each of the strategies discussed above has its own limitations and further research is required before a safe and effective treatment approach is available. Thus, there remains a need to address AMR load and spread.

[0006] Any discussion of documents, acts, materials, devices, articles or the like which has been included in this specification should not be construed as an admission that any or all of those matters form part of the prior art or are general general knowledge in the field relevant to this disclosure existing prior to the priority date of each of the appended claims. Summary of the Invention [Means for solving the problem]

[0007] The present disclosure is based on the recognition by the inventors that there exists a need for novel strategies to combat the spread of certain traits in bacterial populations, such as, for example, AMR, bacterial virulence, and metal resistance, especially in clinical or bioremediation contexts. To this end, the inventors have developed a novel strategy to prevent the acquisition and / or spread of said plasmids by bacterial populations using recombinant conjugative plasmids that contain multiple entry inhibition systems (EES). Plasmid replication incompatibility (Inc) and EES are two plasmid-derived properties that can inhibit the transfer of a plasmid to a recipient bacterium carrying an identical or closely related plasmid. EES are specifically present in most known conjugative plasmid types and can inhibit the entry of closely related plasmids into recipient bacteria by 10-10,000-fold, depending on the plasmid type. The inventors have exploited these plasmid-derived properties to develop probiotic plasmids that can prevent microbiome populations from acquiring AMR or virulence plasmids. Specifically, the inventors developed probiotic plasmids containing multiple variant EES from the AMR plasmid of interest. Incompatibility group F plasmids are the largest group of AMR plasmids and typically harbor multiple replicons. Using their novel approach, the inventors constructed protective probiotic plasmids carrying three genetic variants of the IncF EES gene. The inventors tested the novel probiotic plasmids in in vitro conjugation experiments and found that bacteria carrying these probiotic plasmids could protect over 99.99% of the population from the acquisition of different IncF plasmid variants carrying AMR. The inventors also demonstrated that increasing the expression of the EES gene (e.g., using an inducible promoter) could significantly increase protection against invasive AMR plasmids.

[0008] In one example, the disclosure provides a recombinant plasmid comprising an entry inhibition system (EES) from multiple plasmid variants, where the plasmid variants comprise a gene that confers a trait of interest. In one example, the recombinant plasmid is a conjugative plasmid.

[0009] In one example, the trait of interest is a trait that is undesirable in a bacterial population (e.g., a virulence trait). For example, the trait of interest can be antimicrobial resistance (AMR), bacterial virulence, or heavy metal resistance. In one example, the trait is AMR. In one example, the trait is bacterial virulence.

[0010] In one example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) contains EES from two plasmid variants (e.g., from a virulence plasmid) that contain a gene that confers a trait of interest.

[0011] In one example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) contains EES from at least three plasmid variants (e.g., from a virulence plasmid) that contain a gene that confers a trait of interest.

[0012] The EES in a recombinant plasmid (e.g., a recombinant conjugative plasmid) can be from different incompatibility groups. Alternatively, the EES in a recombinant conjugative plasmid can be from the same incompatibility group.

[0013] In one example, one or more of the EES are from a plasmid variant from an incompatibility group (Inc) selected from IncF, IncI, IncA, IncC, IncL, IncM, IncN, IncX, and IncH, or any other known and unknown Inc group-containing plasmid. For example, one or more of the EES are from a plasmid variant of incompatibility group F (IncF). In some examples, multiple EES in a recombinant conjugative plasmid are from a plasmid variant of IncF (e.g., traS gene variant). In another example, all of the EES in a recombinant conjugative plasmid are from a plasmid variant of IncF (e.g., all of the EES are traS gene variants).

[0014] In one example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) An EES (traS_F variant) comprising a polynucleotide sequence that is at least 70% identical (e.g., at least 75% identical, or at least 80% identical, or at least 85% identical) to the sequence set forth in SEQ ID NO:1; an EES (traS_R100 variant) comprising a polynucleotide sequence that is at least 70% identical (e.g., at least 75% identical, or at least 80% identical, or at least 85% identical) to the sequence set forth in SEQ ID NO:2; and / or The EES includes one or more of the EES (traS_SLT variants) comprising a polynucleotide sequence that is at least 70% identical (e.g., at least 75% identical, or at least 80% identical, or at least 85% identical) to the sequence set forth in SEQ ID NO:3.

[0015] In another example, the recombinant conjugative plasmid is an EES (traS_F variant) comprising a polynucleotide sequence at least 90% identical to the sequence set forth in SEQ ID NO:1; an EES (traS_R100 variant) comprising a polynucleotide sequence that is at least 90% identical to the sequence set forth in SEQ ID NO:2; and / or The EES comprises one or more of the EES (traS_SLT variants) comprising a polynucleotide sequence that is at least 90% identical to the sequence set forth in SEQ ID NO:3.

[0016] In one example, the recombinant conjugative plasmid is An EES (traS_F variant) comprising a polynucleotide sequence that is at least 95% identical (e.g., at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical) to the sequence set forth in SEQ ID NO:1; an EES (traS_R100 variant) comprising a polynucleotide sequence that is at least 95% identical (e.g., at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical) to the sequence set forth in SEQ ID NO:2; and / or The EES (traS_SLT variants) include one or more of the EESs comprising a polynucleotide sequence that is at least 95% identical (e.g., at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical) to the sequence set forth in SEQ ID NO:3.

[0017] In yet another example, the recombinant plasmid (e.g., a recombinant conjugative plasmid) can be An EES (traS_F variant) comprising the polynucleotide sequence set forth in SEQ ID NO:1; EES comprising the polynucleotide sequence set forth in SEQ ID NO:2 (traS_R100 variant), and / or It comprises one or more of the EES (traS_SLT variants) comprising the polynucleotide sequence set forth in SEQ ID NO:3.

[0018] In some examples, a recombinant plasmid (e.g., a recombinant conjugative plasmid) comprises an EES variant, denoted herein as a traS_F variant. In some examples, a recombinant plasmid (e.g., a recombinant conjugative plasmid) comprises an EES variant, denoted herein as a traS_R100 variant. In some examples, a recombinant plasmid (e.g., a recombinant conjugative plasmid) comprises an EES variant, denoted herein as a traS_SLT variant. For example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) may comprise an EES variant, denoted herein as a traS_F variant, and an EES variant, denoted herein as a traS_R100 variant. For example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) may comprise an EES variant, denoted herein as a traS_F variant, and an EES variant, denoted herein as a traS_SLT variant. For example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) may comprise an EES variant, denoted herein as a traS_100 variant, and an EES variant, denoted herein as a traS_SLT variant. For example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) can include an EES variant designated herein as a traS_F variant, an EES variant designated herein as a traS_100 variant, and an EES variant designated herein as a traS_SLT variant.

[0019] Alternatively or in addition, the recombinant plasmid (e.g., recombinant conjugative plasmid) comprises one or more EES from a plasmid variant of incompatibility group L (IncL), incompatibility group C (IncC), incompatibility group M (IncM), and / or incompatibility group A (IncA). In one example, the plasmid comprises an EES from a plasmid variant of incompatibility group L (IncL). In one example, the plasmid comprises an EES from a plasmid variant of incompatibility group C (IncC). In one example, the plasmid comprises an EES from a plasmid variant of incompatibility group M (IncM). In one example, the plasmid comprises an EES from a plasmid variant of incompatibility group A (IncA). In another example, one or more of the EES are from a plasmid variant of incompatibility group L (IncL) and one or more of the EES are from a plasmid variant of incompatibility group C (IncC). In another example, one or more of the EES are from a plasmid variant of incompatibility group L (IncL) and one or more of the EES are from a plasmid variant of incompatibility group M (IncM). In another example, one or more of the EES are from a plasmid variant of incompatibility group C (IncC) and one or more of the EES are from a plasmid variant of incompatibility group M (IncM). In another example, one or more of the EES are from a plasmid variant of incompatibility group L (IncL), one or more of the EES are from a plasmid variant of incompatibility group C (IncC), and one or more of the EES are from a plasmid variant of incompatibility group M (IncM).

[0020] For example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) can be An EES (excL variant) comprising a polynucleotide sequence that is at least 70% identical (e.g., at least 75% identical, or at least 80% identical, or at least 85% identical) to the sequence set forth in SEQ ID NO:9; An EES (excC variant) comprising a polynucleotide sequence that is at least 70% identical (e.g., at least 75% identical, or at least 80% identical, or at least 85% identical) to the sequence set forth in SEQ ID NO: 10; an EES (excM variant) comprising a polynucleotide sequence that is at least 70% identical (e.g., at least 75% identical, or at least 80% identical, or at least 85% identical) to the sequence set forth in SEQ ID NO: 11; and / or The EES may include one or more (or each) of the EES (excA variants) comprising a polynucleotide sequence that is at least 70% identical (e.g., at least 75% identical, or at least 80% identical, or at least 85% identical) to the sequence set forth in SEQ ID NO:12.

[0021] For example, a recombinant conjugative plasmid may be An EES (excL variant) comprising a polynucleotide sequence at least 90% identical to the sequence set forth in SEQ ID NO: 9; An EES (excC variant) comprising a polynucleotide sequence at least 90% identical to the sequence set forth in SEQ ID NO: 10; an EES (excM variant) comprising a polynucleotide sequence that is at least 90% identical to the sequence set forth in SEQ ID NO: 11; and / or The polypeptide may comprise one or more (or each) of the EES (excA variants) comprising a polynucleotide sequence that is at least 90% identical to the sequence set forth in SEQ ID NO:12.

[0022] For example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) can be An EES (excL variant) comprising a polynucleotide sequence that is at least 95% identical (e.g., at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical) to the sequence set forth in SEQ ID NO:9; An EES (excC variant) comprising a polynucleotide sequence that is at least 95% identical (e.g., at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical) to the sequence set forth in SEQ ID NO: 10; an EES (excM variant) comprising a polynucleotide sequence that is at least 95% identical (e.g., at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical) to the sequence set forth in SEQ ID NO: 11; and / or The EES may include one or more (or each) of the EES (excA variants) comprising a polynucleotide sequence that is at least 95% identical (e.g., at least 96% identical, or at least 97% identical, or at least 98% identical, or at least 99% identical) to the sequence set forth in SEQ ID NO:12.

[0023] For example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) can be EES (excL variant) comprising the polynucleotide sequence set forth in SEQ ID NO: 9; An EES (excC variant) comprising the polynucleotide sequence set forth in SEQ ID NO: 10; An EES comprising the polynucleotide sequence set forth in SEQ ID NO: 11 (excM variant), and / or It may comprise one or more (or each) of the EES (excA variants) comprising the polynucleotide sequence set forth in SEQ ID NO:12.

[0024] In one example, one or more of the EESs are operably linked to a constitutive promoter. For example, the constitutive promoter can be selected from a promoter native to the EES, or a strong integron promoter (Pc), or another suitable (including inducible, e.g., ara) promoter.

[0025] Alternatively or in addition, one or more of the EESs are operably linked to an inducible promoter. For example, the inducible promoter can be an L-arabinose inducible promoter.

[0026] In some examples, each EES is operably linked to a separate promoter.

[0027] In some instances, one or more EESs are operably linked to the same promoter.

[0028] In one example, a recombinant plasmid (e.g., a recombinant conjugative plasmid) includes multiple plasmid replication incompatibility (Inc) control regions (inc-controls), such as Inc control regions from a plasmid variant from an Inc group selected from IncF, IncI, IncA, IncC, IncL, IncM, IncX, IncN, IncH, and any other known or unknown Inc group-containing plasmid.

[0029] In some instances, the Inc regulatory region and the EES are from the same Inc group.

[0030] In one example, one or more of the Inc regulatory regions are from a plasmid variant of IncF.

[0031] In one example, the recombinant plasmid (e.g., a recombinant conjugative plasmid) further comprises a selectable marker or gene. For example, the selectable marker or gene can be an antibiotic resistance gene. For example, the selectable marker confers a selectable enzymatic activity.

[0032] The present disclosure also provides a bacterial cell comprising the recombinant conjugative plasmid of the present disclosure.Preferably, the bacterium is a probiotic bacterium.For example, the probiotic bacterium may be selected from the group consisting of members of Enterobacteriaceae, Lactobacillus, Bifidobacteria, Streptococcus, Lactococcus, Enterococcus, Propionibacterium, Faecalibacterium, Pediococcus, Ruminococcus, Megasphaera, and Bacillus.

[0033] The present disclosure also provides compositions comprising one or more of the live bacterial cells described herein.

[0034] In one example, one or more live bacterial cells are freeze-dried. The freeze-dried bacterial cells may be microencapsulated and / or provided within a capsule.

[0035] In one example, the composition is a food or beverage product. For example, the food or beverage product can be a dairy product (e.g., a yogurt drink).

[0036] The disclosure also provides a method for preventing or reducing the acquisition and / or spread of a plasmid that confers a trait of interest within a population of bacteria, the method comprising introducing into the population one or more bacterial cells described herein, or a composition comprising one or more bacterial cells described herein.

[0037] In one example, the trait of interest is an undesirable trait, such as a virulence trait conferred by a virulence plasmid.

[0038] In one example, the trait of interest can be antimicrobial resistance (AMR). According to this example, one or more of the bacterial cells introduced into the bacterial population can contain a recombinant conjugative plasmid that contains the EES from multiple plasmid variants that confer AMR.

[0039] In one example, the trait of interest may be bacterial virulence. According to this example, one or more of the bacterial cells introduced into the bacterial population may contain a recombinant conjugative plasmid that contains the EES from multiple plasmid variants that confer bacterial virulence.

[0040] In one example, the population of bacteria is a population of enterobacteria and the method includes administering one or more bacterial cells, or a composition comprising one or more bacterial cells, to a subject in need thereof. For example, the method may include orally administering one or more bacterial cells, or a composition comprising one or more bacterial cells, to a subject.

[0041] In one example, the subject is a human.

[0042] In one example, the subject is a non-human animal. For example, the non-human animal can be a livestock species or a companion animal.

[0043] In another example, the population of bacteria to which the probiotic bacteria are introduced is a population of bacteria that colonize a plant, and the method comprises contacting the plant or the soil in which the plant is growing with one or more bacterial cells or a composition comprising one or more bacterial cells.

[0044] In another example, the bacterial population to which the probiotic bacteria are introduced is present in an environment selected from a health care environment, a soil environment, an environment comprising a water source, an environment comprising wastewater, an environment comprising industrial waste, an environment comprising agricultural waste, an environment comprising sewage, and / or an environment comprising biosolids, and the method comprises introducing one or more bacterial cells or a composition comprising one or more bacterial cells into the environment. For example, the method can be a method of bioremediation.

[0045] The present disclosure also provides a food product or beverage comprising one or more bacterial cells as described herein, or a composition comprising one or more bacterial cells as described herein.

[0046] In one example, the food product or beverage is a dairy product. For example, the food product or beverage can be yogurt (e.g., drinking yogurt). [Brief description of the drawings]

[0047] [Figure 1] Provided are the traS gene sequences of (A) traS_R100 (SEQ ID NO: 4), (B) traS_F (SEQ ID NO: 5), and (C) traS_SLT (SEQ ID NO: 6) synthesized for cloning into the plasmid backbone. The -35 and -10 regions of the promoter are shaded in green and underlined, the RBS sequence is shown in bold underline, and the coding region is shaded in grey. [Figure 2-1]1 provides vector maps of probiotic plasmids constructed with single IncF entry blocking gene variants: (A) traS_R100, (B) traS_F. [Figure 2-2] A vector map of the probiotic plasmid constructed in the single IncF entry blocking gene variant: (C) traS_SLT is provided. [Diagram 3] The synthetic sequence of TraS_3 encoding the three IncF entry block gene variants traS_R100, traS_F, and traS_SLT is provided, combining restriction sites (HindIII+XbaI) and the natural promoters for traS_R100, traS_SLT, and the integron promoter Pc for tras_F. The -35 and -10 regions of the promoters are shaded and underlined in green, the RBS sequences are shown in bold underline, and the coding regions are shaded in grey. [Figure 4] FIG. 4 provides a vector map of the probiotic plasmid carrying the three IncF traS variants (traS_3) from FIG. [Diagram 5] 1 provides a vector map of the pBAD33_Gm plasmid backbone containing the IncF variant traS_R100 under the control of an arabinose-inducible promoter. [Figure 6] Figure 1 provides a synthetic sequence of TraS_3 encoding the three IncF entry blocker gene variants traS_R100, traS_F, and traS_SLT flanked by XbaI+HindIII restriction sites for cloning in the pBAD33-Gm backbone. The -35 and -10 regions of the promoter are shaded and underlined in green, the RBS sequence is shown in bold underline, and the coding region is shaded in grey. [Figure 7]1 provides a vector map of a probiotic plasmid with a pBAD33_Gm backbone into which the coding sequences of the three IncF entry blocking gene variants traS_R100, traS_F, and traS_SLT have been cloned. The IncF EES variants traS_R100 and traS_SLT are each under the control of an arabinose-inducible promoter, whereas the IncF EES variant traS_F is under the control of its native promoter. [Figure 8] FIG. 1 provides a summary of the results of mating experiments performed with IncF plasmids from donor J53 to recipient BW25113Rf with or without different probiotic plasmid constructs of the present disclosure. [Figure 9] Alignment of different variants of inhibitory proteins present in IncA, C, IncM, and IncL plasmid sequences found in GenBank is provided. (A) All IncC plasmids in GenBank have only one Exc protein type. The Exc proteins of IncC and IncA are classified in the same inhibitory group and prevent each other's entry. (B) and (C) show inhibitory protein variants from IncL and IncM plasmids. [Figure 10] The nucleotide sequence of the exc(L)_exc(C)_fosA3g block is provided. The underlined nucleotides from 5' to 3' are the coding regions of the IncL_exc, IncC_exc, and fosA3 genes, respectively. [Figure 11] A physical map of the conjugative probiotic plasmid PB1.1 (size: 62702 bp) is provided. The two orange regions are for two independent insertion sites. [Figure 12-1] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-2] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-3] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-4] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-5] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-6] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-7] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-8] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-9] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-10] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-11] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-12] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-13] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-14] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-15] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-16] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-17] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 12-18] 1 provides the nucleotide sequence of the probiotic plasmid PB.1.1. [Figure 13]Figure 1 provides a summary of the results of conjugation experiments carried out with IncM, IncC, or IncL plasmids with or without the probiotic plasmid construct PB1.1 of the present disclosure. The blue bars are for the transfer of different AMR plasmids to empty J53Az bacteria during liquid mating experiments. The orange bars are for the transfer of the respective plasmids to J53Az carrying the conjugative probiotic plasmid PB1.1. When the recipient bacteria has the probiotic plasmid, the transfer of the AMR plasmid is significantly reduced. The conjugation frequency is the ratio of conjugants per recipient. The data shown are the average of three independent liquid mating experiments with standard error. [Figure 14] A summary of the results of mouse experiments demonstrating the acquisition of different AMR plasmids with or without the probiotic plasmid construct PB1.1 of the present disclosure is provided. AMR-colonized mice were co-housed (8 hours each day) with control mice not given probiotic plasmid treatment (None) or with probiotic plasmid-treated (Probiotic) mice. AMR plasmid was detected at different time points in exposed mice from the non-treated group (None). No AMR plasmid was detected in mice given the probiotic plasmid (Probiotic). Different colored circles represent different mice in each group. [Figure 15] A summary of the results of antibiotic treatment 120 hours after exposure to AMR-colonized mice is provided. After 120 hours of exposure to AMR plasmid-colonized mice, probiotic plasmid-colonized mice and non-colonized control mice were given CTX in sucrose water for 2 days. Colonization of CTX-resistant bacteria was significantly enhanced in the gut microbiota in mice not colonized with the probiotic plasmid (None), but was detected at very low levels in only 2 out of 9 mice colonized with the probiotic plasmid (Probiotic). Circles of different colors represent different mice in the groups. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0048] Key Points of the Sequence Listing SEQ ID NO:1 provides the polynucleotide sequence of the F plasmid variant entry inhibition system designated traS_R100.

[0049] SEQ ID NO:2 provides the polynucleotide sequence of the F plasmid variant entry inhibition system, designated traS_F.

[0050] SEQ ID NO:3 provides the polynucleotide sequence of the F plasmid variant entry blocking system, designated traS_SLT.

[0051] SEQ ID NO:4 provides the polynucleotide sequence of the F plasmid variant entry inhibition system, designated traS_R100, including the native promoter, RBS, and restriction sites.

[0052] SEQ ID NO:5 provides the polynucleotide sequence of the F plasmid variant entry inhibition system, designated traS_F, including the native promoter, RBS, and restriction sites.

[0053] SEQ ID NO:6 provides the polynucleotide sequence of the F plasmid variant entry inhibition system, designated traS_SLT, including the native promoter, RBS, and restriction sites.

[0054] SEQ ID NO:7 provides the polynucleotide sequence of the construct, which contains three F plasmid variant entry blocking systems, designated traS_R100 containing the native promoter, traS_SLT, and traS_F containing the integron promoter Pc, together with the RBS and flanking HindIII and XbaI restriction sites.

[0055] SEQ ID NO:8 provides the polynucleotide sequence of the construct, which comprises three traS variant sequences flanked by HindIII and XbaI restriction sites: (i) the traS_R100 variant polynucleotide sequence with a consensus RBS, (ii) the traS_F variant polynucleotide sequence with its native promoter and RBS, and (iii) the traS_SLT variant polynucleotide sequence with the araBAD promoter and consensus RBS.

[0056] SEQ ID NO:9 provides the polynucleotide sequence of the C plasmid variant entry inhibition system, designated ExcC.

[0057] SEQ ID NO: 10 provides the polynucleotide sequence of the L plasmid variant entry inhibition system, designated ExcL.

[0058] SEQ ID NO:11 provides the polynucleotide sequence of the M plasmid variant entry inhibition system, designated ExcM.

[0059] SEQ ID NO: 12 provides the polynucleotide sequence of the A plasmid variant entry inhibition system, designated ExcA.

[0060] SEQ ID NO: 13 provides the nucleotide sequence of the exc(L)_exc(C)_fosA3g block.

[0061] SEQ ID NO:14 provides the polynucleotide sequence of the probiotic plasmid PB1.1.

[0062] Detailed Description general technique Throughout this specification, unless specifically stated otherwise or unless the context requires otherwise, references to a single step, feature, composition of matter, group of steps, or group of features or compositions of matter are intended to be interpreted as encompassing one and more (i.e., one or more) of that step, feature, composition of matter, group of steps, or group of features or compositions of matter.

[0063] Those skilled in the art will understand that the present disclosure may be subject to variations and modifications other than those specifically described. The present disclosure is understood to include all such variations and modifications. The present disclosure also includes all of the steps, features, compositions, and compounds individually or collectively referred to or shown in this specification, as well as any and all combinations, or any two or more of such steps or features.

[0064] The present disclosure is not to be limited in scope by the specific examples described herein, which are intended for the purpose of illustration only. Functionally equivalent products, compositions, and methods are clearly within the scope of the present disclosure.

[0065] Any example of the present disclosure herein is to be construed as applying mutatis mutandis to any other example of the present disclosure, unless specifically stated otherwise.

[0066] Unless specifically defined otherwise, all technical and scientific terms used herein are intended to have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in cell culture, molecular genetics, immunology, immunohistochemistry, protein chemistry, and biochemistry).

[0067] Unless otherwise indicated, the recombinant DNA, recombinant protein, cell culture, and immunological techniques utilized in this disclosure are standard procedures, well known to those skilled in the art. Such techniques are described in J. Perbal, A Practical Guide to Molecular Cloning, John Wiley and Sons (1984), J. Sambrook et al. Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press (1989), TA Brown (editor), Essential Molecular Biology: A Practical Approach, Volumes 1 and 2, IRL Press (1991), DMG Lover and BDHames (editors), DNA Cloning: A Practical Approach, Volumes 1-4, IRL Press (1995 and 1996), and FM Ausubel et al. (editors), Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience (1988, including all current editions to date), Ed Harlow and David Lane (editors), Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, (1988), and JE Coligan et al. al. (editors) Current Protocols in Immunology, John Wiley & Sons (including the most recent edition to date), and other sources.

[0068] Throughout this specification, unless the context requires otherwise, the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated step, or element, or integer, or group of steps, elements, or integers, but not the exclusion of any other step, element, or integer, or group of elements or integers.

[0069] The term "and / or," e.g., "X and / or Y," is to be understood to mean either "X and Y" or "X or Y," and is to be interpreted as providing explicit support for both meanings or either meaning.

[0070] As used in this disclosure, including the claims, the words "a" and "an" refer to one or more.

[0071] As used herein, the terms "about" and "approximately" are intended to be understood as interchangeable and generally refer to a range of numbers around a given number, as well as all numbers within a recited range of numbers. Additionally, all numerical ranges herein should be understood to include each integer within the range.

[0072] The terms "for example" and "i.e." as used herein are not intended to be limiting and are used merely as examples and should not be construed to refer only to those items explicitly listed in the present disclosure.

[0073] Plasmids The present disclosure provides recombinant conjugative plasmids that include multiple entry prevention systems (EES) from multiple plasmid variants, where the plasmid variants from which the EES are derived include one or more genes that confer a trait of interest, e.g., a trait that is typically undesirable in a bacterial population. Exemplary traits that are undesirable in a bacterial population include, but are not limited to, antimicrobial resistance (AMR) and bacterial virulence. In some examples, the EES is derived from a pathogenic plasmid variant. As used herein, the term "pathogenic" is understood in the art as causing pathogenesis, e.g., morbidity and / or mortality, of an organism or population of organisms. In general, pathogenic plasmids often carry genes for resistance to antibiotics or heavy metals, genes for metabolism of atypical substrates, or some species-specific characteristic, such as metabolic traits or virulence factors. Thus, the recombinant conjugative plasmids of the present disclosure can include multiple EES from pathogenic plasmid variants carrying genes that confer any one or more of these undesirable traits.

[0074] The plasmids of the present disclosure exploit the properties of EES to inhibit the transfer of plasmids to recipient bacteria carrying the same or closely related plasmids. EES are specifically present in most known conjugative plasmid types and can inhibit the acquisition of closely related plasmids in recipient bacteria by 10-10,000 fold, depending on the plasmid type. The inventors have discovered that recombinant plasmids containing EES from multiple plasmid variants can be used to prevent or reduce the acquisition and / or spread within a bacterial population of a set of closely related plasmid variants (such as pathogenic plasmid variants) that have the same or related EES.

[0075] As used herein, "plasmid" shall be understood to mean a circular, double-stranded DNA molecule that forms an extrachromosomal, self-replicating genetic element that can be used as a vehicle to introduce nucleic acid into bacterial and eukaryotic cells. Bacterial plasmids are usually circular, covalently closed, and supercoiled. In some instances, plasmids can be transferred from one bacterium to another (including bacteria of other species) through a process known as "conjugation." This transfer of genetic material between hosts is one mechanism of horizontal gene transfer. Thus, as used herein, a "conjugative plasmid" shall be understood to be a plasmid that is capable of interhost or horizontal transfer.

[0076] When used in the context of the plasmids of the present disclosure, the term "recombinant" is understood to mean an artificial or synthetic plasmid created using a plasmid backbone and components from one or more plasmids capable of expressing one or more DNA expression cassettes or operons. Those skilled in the art will understand that any number of plasmid backbones can be used to construct the recombinant plasmids of the present disclosure. However, exemplary plasmid backbones include pBCSK+, pBAD33_Gm, pJIBE401, and pJIMKCore_M described herein. Such backbones can be modified to carry genes encoding, among others, replication and partitioning systems, as well as multiple entry inhibition systems.

[0077] However, those skilled in the art will understand that constructs comprising multiple entry prevention systems (EES) from multiple plasmid variants according to the present disclosure can also be delivered to a host bacterium by other recombinant means, such as, for example, episomal phages (pseudolysogeny) or transposable genetic elements or other integrative and conjugative factors. In this regard, while the use of plasmids to introduce multiple EESs described herein into a host bacterium is a particularly preferred embodiment, those skilled in the art will understand that the concept can be extended to other delivery means, and these alternative embodiments are contemplated herein. Thus, in other examples, the present disclosure also provides episomal phages, transposable genetic elements, or other integrative and conjugative factors comprising multiple EESs from multiple plasmid variants, where the plasmid variant from which the EESs are derived contains one or more genes that confer a trait of interest, such as a trait that is typically undesirable in a bacterial population. Exemplary traits that are undesirable in a bacterial population include, but are not limited to, AMR and bacterial virulence.

[0078] As used herein, "entry inhibition system" or "EES" will be understood to mean a genetic element or system that allows entry inhibition. "Entry inhibition" refers to a property of a plasmid whereby a cell containing the plasmid becomes a poor recipient compared to a similar plasmid during additional conjugation cycles. A plasmid entry inhibition system operates by preventing the physical entry of a progeny plasmid into a cell where the progeny plasmid exhibits an inhibition phenotype. The inclusion of an entry inhibition system relieves the plasmid from competing with related plasmids during partitioning during bacterial division. Thus, entry inhibition (i) prevents incompatible progeny plasmids from displacing existing (e.g., less desirable but closely related) plasmids in the host cell, (ii) avoids uneconomical excess DNA transfer, and (iii) avoids death of the recipient cell by lethal conjugation.

[0079] Entry-blocking proteins from diverse sources exhibit variable blocking indices that are not equally effective but can be increased by overexpressing the blocking protein. As used herein, the term "blocking index" refers to the frequency of transfer of a given plasmid to a recipient that does not contain a plasmid divided by the frequency of transfer to a recipient carrying the same plasmid or a plasmid with a similar entry-blocking system. For example, plasmid F was 100-300 times better transferred to a plasmid-free recipient than to an F+ recipient, thus exhibiting an EI of 100-300 in matings between Escherichia coli (Achtman et al., 1977; Achtman and Skurray, 1977). In a preferred example, the blocking index or protection index is the ratio of the conjugation frequency for an empty recipient (without a blocking system) and for a recipient bacterium carrying a probiotic plasmid (containing a clonal blocking gene). The blocking index indicates the fold of inhibition of plasmid transfer. Thus, a higher blocking index value indicates a stronger protection from acquisition of the tested plasmid.

[0080] As described herein, a recombinant conjugative plasmid (or other vehicle for delivery of a DNA construct described herein) comprises multiple EES from multiple plasmid variants. In one example, a recombinant conjugative plasmid comprises EES from two plasmid variants that contain a gene that confers a trait of interest. In one example, a recombinant conjugative plasmid comprises EES from at least three (e.g., three, or four, or five, or six, or seven, or eight, or nine, or ten or more) plasmid variants that contain a gene that confers a trait of interest. In some examples, two or more of the EES in a recombinant conjugative plasmid are from the same incompatibility group. In some examples, all of the EES in a recombinant conjugative plasmid are from the same incompatibility group. In other examples, the EES in a recombinant conjugative plasmid are from different incompatibility groups (e.g., the EES can be from two, three, four or more different incompatibility groups).

[0081] Incompatibility grouping describes the inability of two plasmids to stably coexist in the same bacterial cell strain for several generations. Plasmids that are incompatible with each other are assigned to the same "incompatibility group" or "Inc." Conversely, plasmids that fall into different incompatibility groups may be able to coexist in the same bacterial cell. Thus, "plasmid incompatibility" refers to the inability of plasmids to stably coexist in the same cell if they have similar or identical systems for plasmid replication and / or plasmid partitioning, i.e., the separation of each plasmid into daughter cells during cell division along with an entry blocking gene. Two incompatible plasmids occupying the same cell tend to be separated or partitioned into different cells during cell division in the absence of selection pressure for both plasmids. Stable intracellular coexistence of one plasmid with another requires that each plasmid be able to control its own replication / partitioning, independent of the other, so that a stable copy number can be established and maintained. However, the inability of a given plasmid to maintain a stable copy number in the presence of another plasmid is a hallmark of incompatibility. When two plasmids of the same incompatibility group are found in the same cell, competition for cell sources may occur. Whichever plasmid is able to replicate faster or provide some other advantage will typically be reflected in the unequal degree between the copies tolerated by the incompatibility system. Surprisingly, plasmids can also be incompatible if both have the same function to distribute themselves to daughter cells.

[0082] Plasmids are typically classified into only one of many existing incompatibility groups. There are more than 30 known incompatibility groups. Examples include, but are not limited to, IncN, IncW, IncL, IncM, IncT, IncU, IncW, IncY, IncB / O, IncI1, IncK, IncCom9, IncFI, IncFII, IncFIII, IncHIl, IncHI2, IncX, IncA, IncC, IncD, IncFIV, IncFV / FO, IncFVI, IncHl3, Incl2, IncI, IncJ, IncV, IncP, IncQ, and the like, including variants thereof. Thus, in some examples, one or more of the EES in the recombinant plasmid is derived from a plasmid variant of an incompatibility group (Inc) selected from the above. In some examples, one or more (or all) of the EES in the recombinant plasmid are from an incompatibility group (Inc) plasmid variant selected from IncF, IncI, IncA, IncC, IncM, IncL, IncN, IncX, IncP, and IncH.

[0083] In one particular example, one or more of the EESs are from a plasmid variant of IncF. In another example, all of the EESs are from a plasmid variant of IncF. For example, a recombinant conjugative plasmid can include EESs from at least two (e.g., at least three, or four, or five, or six, or seven, or eight, or nine, or ten or more) plasmid variants of IncF.

[0084] As described herein, in some instances, the entry inhibition system may be derived from a plasmid variant of incompatibility group F, the largest group within the AMR plasmids. Due to their considerable variability in replication systems / genes, it has been difficult to cure and / or protect all plasmids within IncF using existing plasmid-based approaches up to this point (see, for example, Kamruzzaman et al., 2017 and Bikard et al., 2014). The F plasmid exerts its inhibition power using two different EES genes, traT and traS. The majority of the F plasmid inhibition activity is believed to be attributable to TraS (EI of approximately 200 vs. 20 for TraT). The EI of the F plasmid EES is also believed to be gene dosage dependent since. In this regard, Skurray et al. and Achtman et al. (Skurray, Willetts et al. 1976; Achtman, Kennedy et al. 1977) showed that cloning traS and traT into a multicopy plasmid increased the EI to 10,000. In one example, one or more of the EESs in a recombinant conjugative plasmid is a traS gene variant.

[0085] The present disclosure provides three genetic variants of the entry blocking gene traS from the F plasmid, designated traS-R100, traS_F, and traS_SLT, which collectively represent most IncF plasmid mutations.

[0086] In one example, a recombinant conjugative plasmid of the disclosure comprises an EES ("traS_F variant EES") that comprises a polynucleotide sequence that is at least 70% (e.g., at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%) identical to the sequence set forth in SEQ ID NO: 1. For example, a recombinant conjugative plasmid of the disclosure can comprise an EES that comprises a polynucleotide sequence set forth in SEQ ID NO:1.

[0087] In one example, a recombinant conjugative plasmid of the present disclosure comprises an EES comprising a polynucleotide sequence that is at least 70% (e.g., at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%) identical to the sequence set forth in SEQ ID NO: 2 (a "traS_R100 variant EES"). For example, a recombinant conjugative plasmid of the present disclosure can comprise an EES comprising a polynucleotide sequence set forth in SEQ ID NO:2.

[0088] In one example, a recombinant conjugative plasmid of the present disclosure comprises an EES ("traS_SLT variant EES") that comprises a polynucleotide sequence that is at least 70% (e.g., at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%) identical to the sequence set forth in SEQ ID NO: 3. For example, a recombinant conjugative plasmid of the present disclosure can comprise an EES that comprises the polynucleotide sequence set forth in SEQ ID NO:3.

[0089] In some examples, the traS_F variant EES, the traS_R100 variant EES, and the traS_SLT variant EES are combined in a recombinant conjugative plasmid of the disclosure.

[0090] One of skill in the art will appreciate that a recombinant conjugative plasmid containing an F plasmid variant EES gene described herein may further include EES from other incompatibility groups of bacteria (e.g., bacteria known to be pathogenic). Exemplary additional EES genes from other incompatibility groups of bacteria include, but are not limited to, (IncPα plasmids), eex (IncN plasmid pKM101 and IncW plasmid R388), exc (IncI plasmid R144), eexA and eexB (IncHI1 plasmid R27), eexC (IncC plasmids), mbeD (non-self-transmissible ColE1-like plasmids), sec10 / prgA (pAD1 and other sex pheromone plasmids), pif (pSAM2 plasmids), and homologs, orthologs, and variants thereof.

[0091] Alternatively or in addition, a recombinant conjugative plasmid of the present disclosure may include one or more (e.g., two, three, or more) EES from an incompatibility group L (IncL), incompatibility group C (IncC), incompatibility group M (IncM), and / or incompatibility group A (IncA) plasmid variant, which may be alternative to or in addition to the EES from an incompatibility group F plasmid variant described in the preceding examples.

[0092] In one particular example, a recombinant conjugative plasmid of the present disclosure comprises an EES from a plasmid variant of incompatibility group L (IncL) that comprises a polynucleotide sequence that is at least 70% (e.g., at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%) identical to the sequence set forth in SEQ ID NO: 9. For example, a recombinant conjugative plasmid of the present disclosure can comprise an EES that comprises a polynucleotide sequence set forth in SEQ ID NO:9.

[0093] In one particular example, a recombinant conjugative plasmid of the present disclosure comprises an EES from a plasmid variant of incompatibility group C (IncC) that comprises a polynucleotide sequence that is at least 70% (e.g., at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%) identical to the sequence set forth in SEQ ID NO: 10. For example, a recombinant conjugative plasmid of the present disclosure can comprise an EES that comprises a polynucleotide sequence set forth in SEQ ID NO:10.

[0094] In one particular example, a recombinant conjugative plasmid of the present disclosure comprises an EES from a plasmid variant of incompatibility group M (IncM) that comprises a polynucleotide sequence that is at least 70% (e.g., at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%) identical to the sequence set forth in SEQ ID NO: 11. For example, a recombinant conjugative plasmid of the present disclosure can comprise an EES that comprises the polynucleotide sequence set forth in SEQ ID NO:11.

[0095] In one particular example, a recombinant conjugative plasmid of the present disclosure comprises an EES from an incompatibility group A (IncA) plasmid variant that comprises a polynucleotide sequence that is at least 70% (e.g., at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%) identical to the sequence set forth in SEQ ID NO: 12. For example, a recombinant conjugative plasmid of the present disclosure can comprise an EES that comprises a polynucleotide sequence set forth in SEQ ID NO:12.

[0096] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncL described herein and an EES from a plasmid variant of IncC described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0097] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncL described herein and an EES from a plasmid variant of IncM described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0098] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncL described herein and an EES from a plasmid variant of IncA described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0099] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncC described herein and an EES from a plasmid variant of IncM described herein. The recombinant conjugative plasmid can further comprise an EES from a plasmid variant of IncF described herein.

[0100] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncA described herein and an EES from a plasmid variant of IncM described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0101] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncA described herein and an EES from a plasmid variant of IncC described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0102] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncL described herein, an EES from a plasmid variant of IncC described herein, and an EES from a plasmid variant of IncA described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0103] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncL described herein, an EES from a plasmid variant of IncM described herein, and an EES from a plasmid variant of IncA described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0104] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncL described herein, an EES from a plasmid variant of IncC described herein, and an EES from a plasmid variant of IncM described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0105] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncL described herein, an EES from a plasmid variant of IncA described herein, and an EES from a plasmid variant of IncC described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0106] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncC described herein, an EES from a plasmid variant of IncA described herein, and an EES from a plasmid variant of IncM described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0107] In some examples, a recombinant conjugative plasmid of the disclosure comprises an EES from a plasmid variant of IncL described herein, an EES from a plasmid variant of IncC described herein, an EES from a plasmid variant of IncM described herein, and an EES from a plasmid variant of IncA described herein. The recombinant conjugative plasmid may further comprise an EES from a plasmid variant of IncF described herein.

[0108] In some examples, a recombinant conjugative plasmid of the disclosure includes an EES from a plasmid variant of IncF described herein, an EES from a plasmid variant of IncL described herein, an EES from a plasmid variant of IncC described herein, an EES from a plasmid variant of IncM described herein, and an EES from a plasmid variant of IncA described herein.

[0109] Alternatively or in addition, one or more of the EESs included in the recombinant conjugative plasmids of the present disclosure may be derived from a multidrug resistant organism or pathogen, including, but not limited to, organisms belonging to the genus Acinetobacter, Citrobacter, Enterobacter, Enteroccus, Escherichia, Kiebsiella, Serratia, or Staphyloccus. Exemplary multidrug resistant organisms include Acinetobacter, such as ATCC isolate #2894233-696-101-1, ATCC isolate #2894257-696-101-1 ATCC isolate #2894255-696-101-1, ATCC isolate #2894253-696-101-1, or ATCC #2894254-696-101-1. baumannii, ATCC isolate #33128, ATCC isolate #2894218-696-101-1, ATCC isolate #2894219-696-101-1, ATCC isolate #2894224-696-101-1, ATCC isolate #2894218-632-101-1, or ATCC isolate #2894218-659-101-1 Enterobacter cloacae, ATCC isolate #22894228-659-101-1, such as Enterobacter freundii, ATCC isolate #22894251-659-101-1, ATCC isolate #22894264-659-101-1, ATCC isolate #22894246-659-101-1, ATCC isolate #22894243-659-101-1, or ATCC isolate #22894245-659-101-1 Enteroccus facalis, such as ATCC isolate #22894222-659-101-1, ATCC isolate #22894221-659-101-1, ATCC isolate #22894225-659-101-1, or ATCC isolate #22894245-659-101-1; Enteroccus, such as ATCC isolate #51858, ATCC isolate #35667, ATCC isolate #2954833_2694008 ATCC isolate #2954833_2692765, or ATCC isolate #2954836_2694361faecium, Escherichia coli, such as ATCC isolate CGUC11332, CGUC11350, CGUC11371, CGUC11378, or CGUC11393, Kiebsiella pneumonia, such as ATTC isolate #27736, ATTC isolate #29011, ATTC isolate #20013, ATTC isolate #33495, or ATTC isolate #35657, Serratia, such as ATCC isolate #43862, ATCC isolate #2338870, ATCC isolate #2426026, ATCC isolate #SIID2895511, or ATCC isolate #SIID2895538 marcescens, or Staphyloccus aureus such as ATCC isolate #JHH02, ATCC isolate #JHH02, ATCC isolate #JHH03, ATCC isolate #JHH04, ATCC isolate #JHH05, or ATCC isolate #JHH06.

[0110] Alternatively or in addition, one or more of the EESs included in the recombinant plasmid of the present disclosure may be derived from a virulence plasmid carrying virulence genes / virulence determinants encoding virulence factors. For example, pathogenic E. coli, Shigella causing dysentery, and other enterobacteria such as Salmonella typhi (typhoid fever) and Y. pestis (bubonic plague) generally rely on plasmid-derived virulence factors. Thus, one or more of the EESs included in the recombinant conjugative plasmid of the present disclosure may be derived from a virulence plasmid.

[0111] The EES genes / variants can each be linked to a promoter that drives their expression in a host cell. As used herein, the term "promoter" is understood to define a regulatory DNA sequence that is generally located upstream of a gene or sequence to be expressed, and mediates the initiation of transcription by directing RNA polymerase to bind to the DNA and initiating RNA synthesis.

[0112] Promoters for inclusion in the recombinant plasmids of the present disclosure can be endogenous promoters, heterologous promoters, or a combination thereof.

[0113] In some examples, the promoter is a constitutive promoter (e.g., a T7, SP6, T3, integron (Pc), or other suitable constitutive promoter).

[0114] In other examples, one or more of the EES genes may be under the control of an inducible promoter. An inducible promoter may be a nucleic acid sequence or operon system that directs conditional expression of the EES genes in the presence of a certain compound, nutrient, amino acid, sugar, peptide, protein, or condition (e.g., light, oxygen, heat, cold). Alternatively, an inducible promoter may contain one or more repressor elements such that the absence of a certain compound, nutrient, amino acid, sugar, peptide, protein, or condition is required to induce transcription of the EES genes. Any suitable inducible promoter, system, or operon known in the art may be used. Non-limiting examples of inducible promoters contemplated include a lactose regulatory system (e.g., the lactose operon system), a sugar regulatory system, a metal regulatory system, a steroid regulatory system, an alcohol regulatory system, an IPTG inducible system, an arabinose regulatory system (e.g., the arabinose operon system, e.g., the ARA operon promoter, pBAD, pARA, PARAE, ARAE, ARAR-ParaE, portions thereof, combinations thereof, etc.), a synthetic amino acid regulatory system (see, e.g., Rovner AJ, et al., (2015) Nature 518(7537):89-93), a fructose repressor, a tac promoter / operator (pTac), a tryptophan promoter, a PhoA promoter, a recA promoter, a proU promoter, a cst-1 promoter, a tetA promoter, a cadA promoter, a nar promoter, a PL promoter, a cspA promoter, etc., or combinations thereof. In one particular example, the inducible promoter is an L-arabinose inducible promoter.

[0115] In some instances, two or more or all of the EES genes in a recombinant conjugative plasmid are operably linked to the same promoter as the plasmid, i.e., a single promoter driving expression of multiple EES gene variants.

[0116] In other examples, each EES gene variant is operably linked to a separate promoter.

[0117] In some examples, the entry blocking genes are linked to their native promoters and ribosome binding sites (RBS). For example, a recombinant conjugative plasmid can include a traS_F variant EES, a traS_R100 variant EES, and a traS_SLT variant EES, each operably linked to its native promoter and RBS. For example, a recombinant conjugative plasmid of the present disclosure can include a polynucleotide sequence set forth in SEQ ID NOs: 4-6, or a sequence that is at least 70% (e.g., at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or at least 96%, or at least 97%, or at least 98%, or at least 99%) identical to a sequence set forth in SEQ ID NOs: 4-6.

[0118] In some instances, recombinant plasmids of the present disclosure may include a toxin-antitoxin system or an add-on system to prevent non-plasmid-containing segregants from surviving. As used herein, the terms "toxin-antitoxin system," "dependence system," and similar terms (e.g., killer system, kill-antikill, post-partitioning kill, toxin-antidote, plasmid-dependent system, or programmed cell death) are used to describe a genetic system evolved within a plasmid to ensure that a host cell is selectively killed if it does not receive any copies. The molecular basis of a "toxin-antitoxin system" requires the presence of at least two genes: one that expresses a stable toxic agent, i.e., a "toxin," and another that encodes an unstable factor that prevents the lethal action of the gene encoding the toxic agent, i.e., an "antitoxin." The toxin and antitoxin genes may each be operably linked to a promoter within the plasmid to drive expression of the respective gene. Toxin-antitoxin systems for inclusion in bacterial plasmids are known in the art and are contemplated herein.

[0119] Most plasmids are capable of independent replication. In order for a plasmid to replicate independently in a cell (e.g., a bacterial cell), the plasmid must have a stretch of DNA that can act as an "origin of replication". A plasmid that can replicate autonomously in a host cell is also called a replicon. According to the example of the recombinant conjugative plasmid of the present disclosure that can replicate autonomously, the plasmid will include an origin of replication.

[0120] Other plasmids can be stably integrated into the genome of the host cell and thereby are replicated along with the host genome.

[0121] The recombinant conjugative plasmid may further comprise one or more plasmid replication incompatibility (Inc) control regions (inc-control). In one particular example, the one or more inc-control regions are from one or more of the aforementioned plasmid incompatibility groups. For example, the one or more inc-control regions are from a plasmid incompatibility group selected from IncF, IncI, IncA, IncC, IncL, IncM, IncX, IncP, IncN, and IncH. However, one of skill in the art will understand that the inc-control region may be from any known or yet to be identified plasmid incompatibility group.

[0122] The plasmids of the present disclosure may also contain several other genetic elements, such as genes for plasmid-specific replication initiator proteins (Rep), repeating units called iterons, DnaA boxes, and flanking AT-rich regions. In addition, the plasmids may contain one or more nucleic acid segments, genes, promoters, enhancers, activators, multiple cloning regions, or any combination thereof, including segments obtained or derived from one or more natural and / or artificial sources.

[0123] The recombinant conjugative plasmids of the present disclosure may further comprise one or more selectable markers or genes that allow for the selection of cells (e.g., bacterial cells) that contain the plasmid. Selectable marker genes suitable for inclusion in a plasmid will be known to those of skill in the art. In one example, the selectable marker may be an antibiotic resistance gene. Antibiotic resistance genes confer resistance to antibiotic compounds such as, for example, ampicillin, kanamycin, chloramphenicol, tetracycline, rifampicin, neomycin, hygromycin, erythromycin, methotrexate, and gentamicin. In another example, the selectable marker is a gene that confers a selectable enzyme activity, such as beta-galactosidase or the lactose operon.

[0124] In one example, a recombinant plasmid of the present disclosure can include the entry blocking gene variants designated traS_F, traS_R100, and traS_SLT described herein (i.e., pJIMK_traS_3, FIG. 4) operably linked to promoter and RBS sequences flanked by HindIII and XbaI restriction sites in a pBCSK+ backbone. For example, a recombinant plasmid of the present disclosure can include the sequence set forth in SEQ ID NO:7.

[0125] In one example, a recombinant plasmid of the present disclosure can include the entry blocking gene variants designated traS_F, traS_R100, and traS_SLT described herein (by reference to SEQ ID NOs: 1-3), with at least one of the traS variants operably linked to the pBAD arabinose operon promoter described in SEQ ID NO: 8 (FIG. 6). For example, the traS variants can be combined within a pBAD33_Gm backbone (e.g., pJIMK_ara_traS_R100, FIG. 5). For example, a construct containing the traS variants can be cloned into the HindIII+XbaI sites of a pBAB33_Gm backbone to produce pJIMK_ara_traS_3, with the IncF EES variants traS_R100 and traS_SLT each under the control of an arabinose-inducible promoter, and the IncF EES variant traS_F under the control of its native promoter (FIG. 7).

[0126] In one example, a recombinant plasmid of the disclosure can include the entry blocking gene variants designated IncC, IncL, and IncM as described herein (by reference to SEQ ID NOs: 9-11, respectively) operably linked to a promoter and RBS sequence including any suitable restriction sites within a cloning vector, e.g., a pBCSK+ backbone. For example, a recombinant plasmid of the disclosure can include the sequences set forth in SEQ ID NOs: 9-11. Alternatively, a recombinant plasmid of the disclosure can include the sequences set forth in SEQ ID NOs: 11 and 13.

[0127] In one example, a recombinant plasmid of the disclosure can include the entry blocking gene variants designated IncC, IncL, IncM, and IncA described herein (by reference to SEQ ID NOs: 9-12, respectively) operably linked to a promoter and RBS sequence including any suitable restriction sites within a cloning vector, e.g., a pBCSK+ backbone. For example, a recombinant plasmid of the disclosure can include the sequences set forth in SEQ ID NOs: 9-12. Alternatively, a recombinant plasmid of the disclosure can include the sequences set forth in SEQ ID NOs: 11 and 13.

[0128] Probiotic bacteria The present disclosure also provides bacterial cells comprising the recombinant conjugative plasmids described herein, i.e., bacterial cells into which the recombinant conjugative plasmids of the present disclosure have been introduced, or progeny of such bacterial cells. Such bacterial cells expressing incompatibility entry-blocking system genes within a bacterial population can be used as probiotics to prevent or reduce the acquisition and / or spread of plasmids (such as pathogenic plasmids). Thus, the bacteria described herein can be probiotic bacteria.

[0129] When used in connection with the bacteria of the present disclosure, the term "probiotic", "probiotics", or similar terms shall be understood to mean bacteria that enhance the growth and / or health of beneficial bacteria in a particular environment (e.g., the gastrointestinal tract, soil, or water system of a subject). Alternatively or additionally, "probiotic", "probiotics", or similar terms may assist in reducing the growth and / or prevalence of pathogenic bacteria in a particular environment (e.g., the gastrointestinal tract, soil, or health care environment). For example, probiotic bacteria administered to a subject in an appropriate amount should confer a health benefit to the subject (e.g., a human or animal host), such as by improving the gastrointestinal microbial balance. In another example, probiotic bacteria applied or introduced in an appropriate amount to soil, wastewater, biosolids, or other environments may improve the microbial balance in that environment, resulting in one or more beneficial outcomes.

[0130] The probiotic bacteria of the present disclosure are typically non-pathogenic and may demonstrate (i) one or more beneficial functions in the gastrointestinal tract of humans and non-human animals, or (ii) one or more beneficial qualities that make them suitable for bioremediation applications.

[0131] Exemplary probiotic non-pathogenic bacteria include Escherichia coli, non-pathogenic members of the Enterobacteriaceae species, and other Bacillus species include, but are not limited to, Bacillus coagulans; Bacillus coagulans Hammer; and Bacillus brevis subspecies coagulans, Bacillus laevolacticus, Bacillus subtilis, Bacillus uniflagellatus, Bacillus lateropsorus, Bacillus laterosporus BOD, Bacillus megaterium, Bacillus polymyxa, Bacillus licheniformis, Bacillus pumilus, and Bacillus sterothermophilus. Exemplary probiotic Lactobacillus species include, but are not limited to, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus DDS-1, Lactobacillus GG, Lactobacillus rhamnosus, Lactobacillus plantarum, Lactobacillus reuteri, Lactobacillus gasserii, Lactobacillus jensenii, Lactobacillus delbruekii, Lactobacillus, bulgaricus, Lactobacillus salivarius, Lactobacillus plantarum, Lactobacillus fermentum, Lactocobacillus helveticus, and Lactobacillus sporogenes. Exemplary probiotic Sporolactobacillus species include all Sporolactobacillus species, such as Sporolactobacillus P44.Exemplary probiotic Bifidiobacterium species include, but are not limited to, Bifidiobacterium adolescentis, Bifidiobacterium animalis, Bifidobacterium adolescentis Bifidiobacterium bifidum, Bifidiobacterium bifidus, Bifidiobacterium breve, Bifidiobacterium infantis, Bifidiobacterium infantus, Bifidiobacterium longum, and any genetic variants thereof.Other strains that can be used due to their probiotic activity include members of the Lactococcus genus, such as Lactococcus lactis, Lactococcus diacetylactis, Lactococcus cremoris, and Streptococcus (Enterococcus).For example, Enterococcus faecium is commonly used as a probiotic for livestock, and therefore can be utilized as a co-administration agent. Similarly, Ruminococcus species and Megasphaera may be utilized in applications where the bacteria are administered to livestock species as probiotics.

[0132] For example, the probiotic bacteria may be selected from the group consisting of Escherichia, Klebsiella, Citrobacter, Lactobacillus, Bifidobacteria, Streptococcus, Lactococcus, Enterococcus, Propionibacterium, Faecalibacterium, Pediococcus, Ruminococcus, Megasphaera, and Bacillus.

[0133] Exemplary bacteria of non-pathogenic E. coli that can be used as probiotics in the present disclosure because they are capable of colonizing the highly acidic environment of the gastrointestinal tract, particularly the human gastrointestinal tract.

[0134] Transformation of bacterial cells with the recombinant conjugative plasmids of the present disclosure may be carried out by any means known in the art, including, for example, but not limited to, protoplast transformation (see, e.g., Chang and Cohen, 1979, Molecular General Genetics 168:111-115), the use of competent cells (see, e.g., Young and Spizizin, 1961, Journal of Bacteriology 81:823-829, or Dubnar and Davidoff-Abelson, 1971, Journal of Molecular Biology 56:209-221), electroporation (see, e.g., Shigekawa and Dower, 1988, Biotechniques 6:742-751), or conjugation (see, e.g., Koehler and Thorne, 1987, Journal of Bacteriology 169:5771-5278).

[0135] The growth of these various probiotic bacterial species to form cell cultures, cell pastes, and spore preparations is generally well known in the art. Those skilled in the art will be able to determine the appropriate growth / culture conditions depending on whether the bacteria are aerobes, facultative anaerobes, or obligate anaerobes. Such culture methods are known in the art.

[0136] In some examples, probiotic bacteria are encapsulated, for example, to protect bacteria and maintain viability.Protection of bacteria is achieved when the majority of cells are either still viable or still metabolically active, or when compared with unencapsulated cells treated under the same conditions, more of the encapsulated cells are viable.Methods of encapsulation of bacteria (e.g., microencapsulation) are known in the art.

[0137] Alternatively or in addition, the probiotic bacteria may be freeze-dried. The term "freeze-drying" (also known as lyophilisation, lyophilisation or cryo-drying) is used in its usual sense as the cooling of a liquid sample, converting the freezable solution into ice, crystallising the crystallisable solutes, forming an amorphous matrix containing the non-crystallised solutes associated with the non-frozen mixture, followed by evaporation (sublimation) of water from the amorphous matrix. In this process, the evaporation (sublimation) of the frozen water in the material is usually carried out under reduced ambient pressure to allow the frozen water in the material to sublime directly from the solid phase to the gas phase. Freeze-drying typically includes the steps of pre-treatment, freezing, primary drying and secondary drying. Methods of freeze-drying are known in the art. An exemplary method is described in WO2015 / 000972, the entire contents of which are incorporated herein by reference.

[0138] In other examples, the probiotic bacteria may be spray dried or extruded.

[0139] composition Also disclosed herein are compositions (e.g., probiotic compositions) comprising the recombinant conjugative plasmids of the present disclosure and probiotic bacteria. Such compositions can be used to prevent or reduce the spread and / or acquisition of plasmids that confer undesirable traits in bacterial populations (e.g., pathogenicity plasmids described herein). For example, the compositions can be used to prevent or reduce the spread and / or acquisition of plasmids that confer multi-drug resistance (also referred to as AMR), virulence, and / or metal resistance in pathogenic bacterial populations and to aid in colonization (i.e., recolonization) of the gastrointestinal tract or other environments (e.g., as in bioremediation).

[0140] In some examples, the composition may be formulated for administration to a subject. For example, the probiotic bacteria of the present disclosure may be formulated in a composition suitable for administration to a human or animal subject. In one example, the composition is for administration to a human. In another example, the composition is for administration to an animal. Exemplary animals for which the compositions of the present disclosure may be particularly useful include livestock species (e.g., cattle, sheep, horses, pigs, donkeys, poultry), companion animals (e.g., dogs, cats), sport animals (e.g., race horses, camels, greyhounds), and captive wild animals. In one example, the animal is a ruminant. Exemplary ruminant animals include cattle, sheep, goats, buffalo, deer, or camelids. In another example, the animal may be a hindgut fermenter. An exemplary hindgut fermenter is a horse. In another example, the animal may be an avian species, such as poultry.

[0141] In other examples, the composition may be formulated for administration to an environment selected from a healthcare environment, a soil environment, an environment containing a water source, an environment containing wastewater, an environment containing industrial waste, an environment containing agricultural waste, an environment containing sewage, and / or an environment containing biosolids.

[0142] The probiotic bacteria and the composition comprising the probiotic bacteria may be formulated for administration or application by any route determined to be suitable by a person skilled in the art. For example, according to the example where the probiotic bacteria and the composition comprising the probiotic bacteria is for administration to a subject, the composition may be formulated for oral administration (e.g., ingestible liquid or solid, oral drench, feed additive, food (e.g., dairy products such as drinking yogurt), or capsule), topical administration (e.g., lotion or cream), intranasal administration, or parenteral administration. In one example, the composition of the present disclosure is formulated for oral administration, for example, as a food, drink, bolus, drench, or capsule. Thus, the composition may further comprise one or more physiologically acceptable excipients, carriers, or additives suitable for ingestion by humans or non-human animals. Physiologically acceptable excipients, carriers, or additives suitable for ingestion by humans or non-human animals are known in the art and described herein. Such carriers can, for example, allow the probiotic bacteria of the present disclosure to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like. The choice of carrier will depend on the form of the composition, the intended method of administration, the intended shelf life, and storage considerations. In some examples, the composition can be a food or beverage product (e.g., a dairy product such as drinking yogurt). In some examples, the composition can be a tablet, pill, caplet, or capsule. Without being limited thereto, suitable excipients include fillers such as sugars, including, but not limited to, lactose, sucrose, mannitol, and sorbitol; cellulose preparations, including, but not limited to, corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidone (PVP). If necessary, disintegrating agents may be added, such as, but not limited to, the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.The composition that can be used orally includes, but is not limited to, capsules made of gelatin, and soft, sealed capsules made of gelatin and plasticizers such as glycerol or sorbitol. In some examples, the composition can be formulated in a buffer. It will be understood by those skilled in the art that suitable buffers can be used. Examples of suitable buffers include, but are not limited to, phosphate, calcium carbonate, bicarbonate, citrate phosphate, and histidine. In other examples, the composition can be formulated with a carrier that has a low oxygen diffusion rate, such as, for example, ingestible oil. The composition can further include an antioxidant.

[0143] In some examples, the compositions may include preservatives or stabilizers. Additionally, depending on the method of manufacture, the compositions may include one or more cryoprotectants known in the art.

[0144] According to the example where the composition is a food product (such as a dairy product), a feed / supplement, or a beverage product, the probiotic bacteria or the composition comprising the probiotic bacteria can be prepared by or shipped to a manufacturer. The probiotic bacteria or the composition comprising the probiotic bacteria can then be formulated into a food product, a feed / supplement, or a beverage product by adding further ingredients that are appropriate for the product.

[0145] In some examples, the compositions of the present disclosure are stable when stored at ambient room temperature (e.g., 20° C. and 25° C.), such as when stored at ambient room temperature for at least one month or more. In other examples, such as those in which the compositions are formulated as dairy or beverage products, the compositions may need to be refrigerated to maintain viability of the probiotic bacteria.

[0146] In some examples, the compositions of the present disclosure are packaged in a container. The container may contain a single dose or multiple doses of the compositions described herein.

[0147] Preferably, the composition comprises the probiotic bacteria of the present disclosure in an amount sufficient to provide at least in part a benefit to the health of the subject or the environment to which it is administered.

[0148] According to the application in which the probiotic composition is formulated for use in humans or non-human animals, the composition will contain probiotic bacteria in an amount sufficient to provide at least partial health benefits to humans or non-human animals. An amount sufficient to achieve this is defined as a "therapeutically effective amount". An effective amount for this purpose may vary depending on several factors known to those skilled in the art, including, but not limited to, the subject's species, the anatomy of the digestive system (e.g., four-chambered or single-chambered stomach), the subject's size / weight, the composition of the subject's diet (current and future), whether the subject is lactating, whether the subject is pregnant, and the results to be achieved. Thus, the appropriate dosage of probiotic bacteria (e.g., CFU per strain) to be formulated in the composition of the present disclosure can be determined by those skilled in the art, taking into account one or more of the above factors.

[0149] In one example, a unit or dosage of the composition of the present disclosure is about 10 2 CFU ~ approx. 10 14 CFU, or about 10 3 CFU ~ approx. 10 13 CFU, or about 10 4 CFU ~ approx. 10 13 CFU, or about 10 5 CFU ~ approx. 10 13 CFU, or about 10 6 CFU ~ approx. 10 13 CFU, or about 10 6 CFU ~ approx. 10 12 CFU, or about 10 7 CFU ~ approx. 10 11 CFU, or about 10 8 CFU ~ approx. 10 10 CFU, or about 10 9 CFU ~ approx. 10 10 CFU of the probiotic bacteria of the present disclosure. For example, each unit or dosage of the composition of the present disclosure may contain about 5×10 7 CFU, or approximately 6 x 10 8CFU, or about 10 9 CFU, or about 10 10 It may contain CFU of probiotic bacteria.

[0150] method Also provided herein is a method for preventing or reducing the spread and / or acquisition of a plasmid that confers an undesirable trait (such as, for example, a virulence plasmid described herein) in a bacterial population, the method comprising introducing a probiotic bacterium described herein or a composition comprising a probiotic bacterium described herein into the population.

[0151] In one example, the method is for preventing or reducing the spread and / or acquisition of plasmids that confer antimicrobial resistance in a bacterial population. For example, the method can include introducing a probiotic bacterium as described herein or a composition comprising a probiotic bacterium as described herein into a bacterial population, where one or more of the probiotic bacterial cells introduced into the population comprises a recombinant conjugative plasmid that comprises an entry prevention system (EES) from multiple plasmid variants that confer AMR, as described herein.

[0152] In one example, the method is for preventing or reducing the spread and / or acquisition of a plasmid that confers bacterial virulence in a bacterial population. For example, the method can include introducing a probiotic bacterium as described herein or a composition comprising a probiotic bacterium as described herein into a population, where one or more of the probiotic bacterial cells introduced into the population comprises a recombinant conjugative plasmid that comprises the EES from a plurality of plasmid variants that confer bacterial virulence, as described herein.

[0153] In another example, the method is for preventing or reducing the spread and / or acquisition of plasmids conferring heavy metal resistance in a bacterial population. For example, the method can include introducing a probiotic bacterium as described herein or a composition comprising a probiotic bacterium as described herein into a bacterial population, where one or more of the probiotic bacterial cells introduced into the population comprises a recombinant conjugative plasmid comprising an EES from a plurality of plasmid variants conferring heavy metal resistance as described herein.

[0154] For example, the method may prevent or reduce the spread and / or acquisition of plasmids that confer virulence traits (such as AMR and / or bacterial virulence) in bacterial populations of the gastrointestinal tract during conjugation cycles. In one example, the method may prevent or reduce the spread and / or acquisition of plasmids that confer virulence traits to bacteria of the Enterobacteriaceae family. The "Enterobacteriaceae" family includes 14 major genera and 6 additional genera that are known to have different characteristics. Typical examples are Escherichia, Salmonella, and Klebsiella. Virulence genes are usually found in enterobacteria on large plasmids (approximately 60 kb or larger). Enterobacteria are generally pathogens that infect the gastrointestinal tract of birds and / or mammals. The disclosed method may be utilized to target enterobacterial populations in the intestine and introduce recombinant conjugative plasmids to the progeny of the bacterial population in subsequent conjugation cycles. In doing so, the methods may prevent or reduce the spread and / or acquisition of plasmids that confer pathogenic traits (such as AMR and / or bacterial virulence) to bacterial populations in the gut.

[0155] In another example, the method is for preventing or reducing the spread and / or acquisition of a virulence plasmid described herein in a bacterial population in an environment. The environment to which the probiotic bacteria or a composition comprising the probiotic bacteria is introduced may be selected from a health care environment, a soil environment, an environment comprising a water source, an environment comprising wastewater, an environment comprising industrial waste, an environment comprising agricultural waste, an environment comprising sewage, and / or an environment comprising biosolids. Thus, in one example, the method may be used for bioremediation.

[0156] The reduction in the spread or acquisition of virulence plasmids in the bacterial population can be any reduction, such as a reduction by at least 10%, such as at least 15%, or at least 20%, or at least 25%, or at least 30%, or at least 35%, or at least 40% or more, compared to the prevalence of virulence plasmids in a bacterial population to which the probiotic bacteria or the present disclosure has not been introduced. The reduction in the spread or acquisition of virulence plasmids in the bacterial population can result in one or more therapeutic outcomes. As used herein, the terms "treating", "treat", or "treatment" and variations thereof refer to clinical interventions using non-pathogenic bacteria designed to alter the natural course of the individual or cells being treated during the course of a clinical pathology, and can also refer to environmental remediation efforts. The desired effects of treatment when used in relation to a biological organism or infection include amelioration, elimination, reduction, prevention, or other relief from, or management of, the harmful effects of the biological organism, either in the subject's intestine or other environment, by improving and / or controlling the colonization of pathogenic bacteria carrying such traits within the gastrointestinal tract or other environment of both humans or animals, through curing pathogenic populations from multi-drug resistance, or metal resistance, or virulence (e.g., of Enterobacteriaceae).

[0157] In one example, the probiotic bacteria of the present disclosure or a composition comprising the probiotic bacteria of the present disclosure is administered one or more times daily, weekly, biweekly, monthly, or bimonthly, with the daily, weekly, biweekly, monthly, or bimonthly dosage comprising the amounts of probiotic bacteria described above.

[0158] In some examples, the probiotic bacteria or compositions comprising the probiotic bacteria are administered to a human or animal subject. In one example, the probiotic bacteria or composition is administered to a human. In another example, the probiotic bacteria or composition is administered to an animal. Exemplary animals for which the probiotic bacteria and compositions of the present disclosure may be particularly useful are described herein.

[0159] As described herein, the probiotic bacteria and compositions may be administered by any route determined to be suitable by a person skilled in the art. For example, according to examples in which the probiotic bacteria and compositions are administered to a human or animal subject, the compositions may be formulated for oral (e.g., ingestible liquid or solid, oral drench, feed additive, food (e.g., dairy product), or capsule), topical (e.g., lotion, cream, or gel), intranasal, or parenteral administration. In one example, the compositions of the present disclosure are administered orally, for example, as a food, drink, bolus, drench, or capsule.

[0160] In one example, probiotic bacteria or compositions comprising probiotic bacteria can be administered as topical creams, lotions or gels.For example, creams, lotions or gels comprising probiotic bacteria can be effective in reducing or preventing the acquisition or spread of pathogenic plasmids in bacterial populations on the skin, thereby controlling antibiotic-resistant pathogens on the skin.In this regard, pathogenic Pseudomonas, Staphylococcus and / or Enterococci are frequently associated with severe and unpleasant infections.

[0161] Preferably, the probiotic bacteria is administered to the subject in a therapeutically effective amount.As described herein, this may vary depending on several factors known to those skilled in the art, including but not limited to the species of the subject, the anatomical structure of the digestive system (e.g., four-chambered or single-chambered stomach), the size / weight of the subject, the composition of the subject's diet (current and future), whether the subject is lactating, whether the subject is pregnant, and the results to be achieved.Therefore, the appropriate dosage of the probiotic bacteria (e.g., CFU per strain) that is formulated in the composition of the present disclosure can be determined by those skilled in the art, taking into account one or more of the above factors.

[0162] In one example, the unit or dosage of the composition administered to a subject is about 10 2 CFU ~ approx. 10 14 CFU, or about 10 3 CFU ~ approx. 10 13 CFU, or about 10 4 CFU ~ approx. 10 13 CFU, or about 10 5 CFU ~ approx. 10 13 CFU, or about 10 6 CFU ~ approx. 10 13 CFU, or about 10 6 CFU ~ approx. 10 12 CFU, or about 10 7 CFU ~ approx. 10 11 CFU, or about 10 8 CFU ~ approx. 10 10 CFU, or about 10 9 CFU ~ approx. 10 10 CFU of the probiotic bacteria of the present disclosure. For example, the method may include about 5×10 7 CFU, or approximately 6 x 10 8 CFU, or about 10 9 CFU, or about 10 10 The method may include administering a composition comprising CFU of probiotic bacteria.

[0163] Working Example Example 1: Probiotic plasmids containing a single inhibitory gene inhibit IncF plasmid transfer Probiotic plasmids pJIMK_traS_F, pJIMK_traS_R100, and pJIMK_traS_SLT were constructed by cloning different traS variants from IncF plasmid into the pBCSK+ backbone.

[0164] Bacterial strains and plasmids used: Table 1 provides details of the various bacterial strains and plasmids, denoted pJIMK_traS_F, pJIMK_traS_R100, pJIMK_traS_SLT, used to generate the probiotic plasmids. [Table 1]

[0165] Analysis of the entry inhibition system in IncF plasmids: We obtained the traS sequence responsible for entry inhibition in IncF plasmids and examined those IncF plasmids available in GenBank, then performed multiple sequence alignments using MEGAX software. BlastN and BlastP searches were then performed against the traS nucleotide and amino acid sequences. Three major variants of the traS sequence were identified from the IncF plasmid sequences available in GenBank. These three traS variants were named traS_F, traS_R100, and traS_SLT. Variant traS_F was obtained from E. coli K-12 plasmid F (GenBank accession number AP001918.1), traS_R100 was obtained from Shigella flexneri plasmid R100 (GenBank accession number AP000342.1), and traS_SLT was obtained from Salmonella typhimurium plasmid pSLT (GenBank accession number AE006471.2). The complete nucleotide sequences of these three trsS variants, designated traS_R100, traS_F, and traS_SLT, are set forth in SEQ ID NOs: 1-3, respectively.

[0166] Construction of probiotic plasmids: The g-blocking factors (IDT, USA) of the traS_R100, tras_F, and traS_SLT genes, containing the natural promoter and ribosome binding site (RBS), were artificially synthesized with appropriate restriction sites (Figures 1A-C, and SEQ ID NOs: 4-6, respectively).

[0167] The synthesized traS_R100, traS_SLT, and traS_F genes were then digested by HindIII+BamHI, BamHI+EcoRI, and BamHI+XbaI restriction enzyme combinations at 37°C for 1 h, respectively. The digested DNA samples were then purified using a PCR purification kit (Thermo Fisher, USA). At the same time, the cloning vector pBCSK+ (chloramphenicol resistant) was digested with each restriction enzyme combination for 2 h and then purified. The purified traS gene variants were then separately cloned into the cloning vector pBCSK+ to construct the probiotic plasmids pJIMK_traS_R100, pJIMK_traS_F, and pJIMK_traS_SLT (Figure 2). These probiotic plasmids were transformed into rifampicin-resistant E. coli BW25113Rf to produce BW25113Rf(pJIMK_traS_R100), BW25113Rf(pJIMK_traS_F), and BW25113Rf(pJIMK_traS_SLT). BW25113Rf carrying the probiotic plasmid and empty BW25113Rf were then used as recipients for the transfer of the respective IncF plasmids from the donor J53 strain (Table 2). [Table 2]

[0168] In vitro conjugation: In vitro plasmid conjugation was measured using a standard filter mating experiment (Rodriguez-Grande and Fernandez-Lopez 2020). Donor and recipient bacteria containing the respective plasmids (Table 2) were grown overnight in LB medium containing the appropriate antibiotics. Cultures (1 mL) were harvested by centrifugation at 10,000 g for 5 min, washed twice with 1 mL saline, and suspended in 50 μL saline. Donor and recipient suspensions were mixed. The mixture was placed on a nitrocellulose filter (Amersham Hybond-C extra, 82 mm) on an LB agar plate and then incubated overnight at 37 °C. A mixture of cultures was harvested in 5 mL saline, and 100 μL of the mating mixture with different dilutions was spread on nutrient agar plates containing rifampicin (90 μg / mL) and plasmid-specific antibiotics, which confer resistance to the progeny plasmids, and incubated overnight at 37 °C. The conjugation frequency was then determined by counting transconjugant colonies and dividing the number of transconjugants by the number of donor bacteria. Furthermore, colonies were patched onto CHROMagar Orientation plates containing the appropriate antibiotics to ensure that they were not spontaneous rifampicin-resistant mutants of the donor strain. The presence of progeny plasmid genes within the transconjugants was confirmed by colony PCR using single colonies as templates.

[0169] Inhibition index / protection index measurement: The inhibitory index or protection index is the ratio of the conjugation frequency of the empty recipient (without the inhibitory system) to the recipient bacteria containing the probiotic plasmid (containing the clonal inhibitory gene). The inhibitory index indicates the fold difference in the inhibition of plasmid transfer. Thus, a higher inhibitory index value indicates a stronger protection from the acquisition of the tested plasmid.

[0170] Probiotic plasmids containing single inhibitory genes inhibited conjugative transfer of different IncF plasmids in recipient bacteria by almost 200-fold (Table 2, Figure 8). This inhibition of transfer was specific to different plasmid types. For example, tras_R100 in recipient bacteria strongly inhibited transfer of R100 plasmids.

[0171] Example 2: Probiotic plasmids containing combinations of blocking gene variants inhibit several IncF plasmids from conjugative transfer. Since the three variants of traS identified by the present inventors (i.e., traS_R100, traS_SLT, and tras_F) represent the majority of IncF plasmids present in the GenBank database, the present inventors combined all three traS gene variants of IncF plasmids with their native promoters for traS_R100, traS_SLT, and with the integron promoter Pc for traS_F, and with their native RBS into a single vector system to construct a probiotic plasmid to protect the host bacterium from the acquisition of most IncF plasmids. A new probiotic plasmid, designated pJIMK_traS_3, was constructed by combining two of the three traS variants with their native promoters and one of them with the integron promoter Pc, with their RBS flanked by HindIII and XbaI restriction sites, into a single construct (SEQ ID NO: 7). The restriction digested and purified trsS-3 gene was then cloned into the HindIII+XbaI sites of pBCSK+ to construct pJIMK_traS_3 (Figures 3 and 4). The probiotic plasmid pJIMK_traS_3 was then transferred to BW25113Rf to construct BW25113Rf(pJIMK_traS_3) and used for conjugative transfer of different IncF plasmid variants from strain J53 to measure the level of transfer inhibition. We were able to show that bacteria carrying the probiotic plasmid pJIMK_traS_3 were able to successfully protect recipient bacteria from acquiring all IncF plasmid variants tested, similar to the protection provided by the traS gene against certain F plasmids (Table 3, Figure 8). This result suggests that probiotic plasmids containing combinations of different inhibitory gene variants can be constructed to prevent the acquisition of various plasmid types. Our results also suggest that a probiotic plasmid containing a combination of the three traS blocking gene variants is able to prevent the acquisition of the majority of IncF plasmid types. [Table 3]

[0172] Example 3: Increasing the expression of one or more inhibitor genes in a probiotic plasmid significantly increases protection against the target plasmid. In this example, we evaluated whether increasing the expression of blocking traS variants increases the inhibition of transfer of plasmids in recipient bacteria. Expression of a gene of interest can be conveniently controlled by cloning the gene into an expression vector under an arabinose-inducible promoter containing the araB and araC genes. In this example, pBAD33_Gm expression vector (gentamycin resistance, plasmid #65098, Addgene) was used to generate expression vectors containing blocking gene traS variants to control the expression of the traS variant gene by adding different concentrations of arabinose.

[0173] The effect of traS gene expression on inhibition of plasmid transfer in recipient bacteria was specifically evaluated for variant traS_R100. Briefly, the traS_R100 sequence containing the consensus RBS region was synthesized and cloned into the HindIII+XbaI sites of pBAD33_Gm to construct pJIMK_ara_traS_R100 (Figure 5). It was found that increasing the expression of traS_R100 in recipient bacteria from the probiotic plasmid pJIMK_ara_traS_R100 by arabinose (0.2%) significantly increased the inhibition of R100 plasmid transfer to recipient bacteria (Table 4). This result suggests that high levels of traS inhibitory protein in recipient bacteria can significantly improve the level of protection from acquisition of the target plasmid (R100). [Table 4]

[0174] To improve the expression of all three traS variants from a single probiotic plasmid and deliver a high level of protection against the acquisition of most of the IncF plasmids, the three traS variants were synthesized with the araBAD promoter (Figure 6) and cloned into pBAD33_Gm to construct pJIMK_ara_traS_3 (Figure 7). More specifically, the triple traS construct contained three traS variants flanked by HindIII and XbaI restriction sites in the three traS variant sequences: (i) the consensus RBS containing the traS_R100 sequence, (ii) traS_F containing its native promoter and RBS, and (iii) traS_SLT (SEQ ID NO: 8) containing the araBAD promoter and consensus RBS. The triple traS construct was then restriction digested, purified, and cloned into the HindIII+XbaI sites of pBAB33_Gm to construct pJIMK_ara_traS_3 (Figure 7).

[0175] In this probiotic plasmid, traS_R100 and traS_SLT were directly regulated from the araBAD promoter, whereas traS_F was under the control of the native promoter and the araBAD promoter. The probiotic plasmid pJIMK_ara_traS_3 was then transferred to strain BW25113Rf, which was used as a recipient in the conjugative transfer of different IncF plasmids from E. coli J53 (Table 5). The recipient bacteria were induced with 0.2% arabinose for 1 h, after which the donor and recipient were mixed for the mating experiment. Surprisingly, it was found that induction of the traS_3 gene with arabinose significantly increased the conjugative transfer inhibition of all three tested different IncF plasmids (Table 5, Figure 8). This suggests that increasing the expression of the inhibitory gene from the probiotic plasmid in bacteria can improve the protection from the acquisition of any target plasmid. [Table 5]

[0176] Example 4: Conjugative probiotic plasmids to protect bacteria from invasion by IncM, IncL, IncC, and IncA plasmid types in vitro. In this example, we designed and constructed conjugative probiotic plasmids containing Exc protein sequences from multiple Inc plasmid types and evaluated their ability to protect bacteria from invasion by multiple incompatibility types of AMR plasmids.

[0177] The Exc protein sequences of IncM, L, C, and A plasmid types were analyzed. We analyzed the Exc protein sequences of IncM, IncL, IncC, and IncA plasmid types that were available in Genbank.

[0178] Based on this analysis, we identified that all IncC plasmids in GenBank carry a single Exc protein type. Although the Exc of IncA is slightly different from the Exc of IncC plasmids (see FIG. 9A), recent experimental studies have identified that both Exc proteins are classified into the same Exc group despite some amino acid sequence variations, demonstrating that IncCExc can efficiently inhibit both IncC and IncA group plasmids (Humbert et al., 2019).

[0179] IncL plasmids were also predominantly represented by a single Exc type (see IncL_Exc_1 in Figure 9B). In this regard, 95% (233 / 249) of IncL plasmids in GenBank carried this unique type of Exc protein, while 5% (16 / 249) of IncExcs had one to two aa mutations compared to the predominant Exc type. This suggests that all Exc variants in IncL plasmids are closely related to each other and that the major variant (IncL_Exc_1) is able to block all IncL plasmids.

[0180] IncM plasmids carry two major types of Exc proteins that vary by only two amino acids and collectively represent >99% of IncM plasmids in GenBank (see Figure 9C).

[0181] We predicted the promoter regions associated with these major Exc variants in IncL, M, and C plasmids.

[0182] Construction of conjugative probiotic plasmids to protect bacteria from invasion of IncM, L, C and A plasmid types We previously identified the IncM plasmid pJIBE401 with high in vivo conjugation efficiency. In this study, the high conjugation efficiency IncM plasmid backbone of pJIBE401 was used as a backbone to construct a probiotic plasmid to protect bacteria from the invasion of four different plasmid types. A ∼28.0 kb multiple resistance region (MRR) carrying multiple antibiotic resistance genes and transposable elements was deleted from the IncM plasmid pJIBE401 and replaced with a tetracycline resistance gene (tetA) to generate a plasmid backbone designated pJIMK45 (Kamruzzaman et al., 2017).

[0183] We used pJIMK45 as the backbone of the conjugative probiotic plasmid. This backbone already contained the exc gene of the IncM plasmid type. We then introduced the exc genes from IncL and IncC plasmids to produce the conjugative probiotic plasmid (PB1). Briefly, the exc gene sequences from IncL and IncC plasmids, together with their native promoters and ribosome binding sites, were combined with the fosA3 gene and flanked on both sides by 60 bp sequences homologous to the regions flanking the tetA gene in pJIMK45 (the synthetic sequence is shown as "gBlock", FIG. 10). The g-block was commercially synthesized and introduced into the pJIMK45 backbone plasmid using a homologous recombination-based allelic exchange method to replace the tetA gene. To insert the g-block, E. coli strain UB5201Rf carrying pJIMK45 was transformed with the lambda Red recombinase plasmid pKM200 (chloramphenicol resistance) and selected on tetracycline + chloramphenicol plates at 30°C. Electrocompetent cells were prepared from UB5201Rf (pJIMK45 + pKM200) and transformed with the PCR amplified g-block of excL-excC-fosA3 by electroporation. Transformants were selected on fosfomycin resistance plates. Selected transformants were then checked for sensitivity to tetracycline and the insertion event was confirmed by PCR and Sanger sequencing.

[0184] The resulting conjugative probiotic plasmid, designated PB1, had an intact pemIK toxin-antitoxin system that ensured its stable maintenance in the bacterial population. To make it unstable, the pemK toxin gene was deleted by replacing it with the tetA gene. The resulting unstable probiotic plasmid was designated "PB1.1". The conjugative probiotic plasmid PB1.1 is lost from the bacteria in the absence of selection pressure. The physical map and nucleotide sequence of the probiotic plasmid PB1.1 are shown in Figures 11 and 12, respectively. The PB1.1 sequence is set forth in SEQ ID NO:13.

[0185] Ability of the conjugative probiotic plasmid PB1.1 to prevent invasion by IncM, IncL, and IncC plasmids in bacteria. The probiotic plasmid PB1.1 was then tested for its ability to prevent bacterial invasion by AMR plasmids of the IncM, IncL, and IncC groups using standard liquid mating experiments.

[0186] Briefly, donor and recipient bacteria were grown overnight in 10 mL of LB-Lennox broth medium containing the appropriate antibiotics. Cultures were washed twice with an equal volume of sterile saline (0.85% NaCl) and resuspended in 10 mL of LB_Lennox broth. The OD of each culture was 600 The pH was adjusted to 2.0, and 1 mL of each donor and recipient culture was mixed and placed in a 15 mL Falcon tube. The mating mixture was incubated at 37°C for 20 h without shaking. Mating was terminated by vortexing the mating mixture for 10 s. The mating mixture was then serially diluted in saline and plated on LB-Lennox agar plates containing sodium azide (100 mg / mL) and cefotaxime (8 mg / mL) to select for transconjugants. The conjugation frequency is the ratio of the total number of transconjugants to the number of recipient bacteria added to the conjugation mixture. E. coli NH78Rf containing IncM plasmid pJIBE401, IncL plasmid pJIE1335, or IncC plasmid pEc158 was used as the donor bacteria, and sodium azide-resistant bacteria J53Az and J53Az carrying the probiotic plasmid PB1.1 were used as recipients for each plasmid transfer.

[0187] The antibiotic resistance IncM, IncL, and IncC plasmids could be easily transferred to the recipient bacteria J53Az after 20 hours of liquid mating experiments, but the transfer of these plasmids to J53Az(pPB1.1) was significantly reduced after the same mating time (Figure 13). The conjugative probiotic plasmids protected more than 99.9% of the recipient bacterial population from the invasion of different groups of AMR plasmids during the mating experiments. This study showed that the single probiotic plasmid PB1.1 in the recipient bacteria could significantly prevent the acquisition of the tested IncM, IncL, and IncC plasmids.

[0188] The characteristics of the bacterial strains and plasmids used in this study are shown in Table 6. [Table 6]

[0189] Example 5: Probiotic plasmid PB1.1 protects the mouse microbiota from the acquisition of different AMR plasmids. In this example, we evaluated the ability of the conjugative probiotic plasmid PB1.1 to protect the mouse gut microbiota from acquisition of different AMR plasmid types listed in Table 6 (including pJIBE401, pJIE1335, and pEc158) during accidental exposure to infected feces via coprophagy.

[0190] Test mice were colonized with the probiotic plasmid PB1.1, whereas control mice were fed normal chow without any supplementation. All mice (i.e., test and control) were exposed to mice colonized with three different common AMR plasmid types. All mice were housed in groups of three as biological replicates within the experiment.

[0191] Sodium azide-resistant E. coli J53Az carrying the probiotic plasmid PB1.1 and rifampicin-resistant E. coli NH78Rf carrying a different AMR plasmid were fed to mice in 8% sucrose in water.

[0192] Test and control mice were co-housed with AMR-colonized mice for 8 hours each day, with or without PB1.1 in 8% sucrose water, and then separated for 16 hours. AMR plasmid-colonized mice were co-housed with either probiotic plasmid-colonized or control mice for a total of 96 hours (4 days) during the experiment.

[0193] Fresh feces were collected and examined on specific antibiotic-containing ChromAgar plates (supplemented with 8 μg / mL CTX for AMR plasmids or 200 μg / mL fosfomycin for probiotic plasmids) and quantified by measuring colony formation using serial dilutions.

[0194] After a total of 48 hours of exposure to infected mice, the AMR plasmid appeared in different mice from the non-colonized control group, and all control mice were colonized with AMR within 96 hours (4 days equivalent) of exposure. In contrast, the AMR plasmid was not detected in any mice that received the probiotic plasmid until 80 hours after the first exposure (Figure 14). One mouse from the probiotic group IncC showed very low levels of AMR plasmid infection after 96 hours of exposure. These data indicate strong protection against acquisition and colonization by the AMR plasmid after long-term co-housing with highly AMR plasmid-colonized mice.

[0195] PCR performed at 96 hours revealed AMR plasmid DNA in all mice (data not shown), confirming that the AMR plasmid had been ingested. These data suggested that the ingested AMR plasmid was not able to colonize those mice that had received overnight probiotic plasmid therapy to levels that could be readily detected by standard culture methods, even after regular exposure and ingestion of common AMR plasmid types.

[0196] As a test of protection, both probiotic-colonized mice (AMR culture negative but PCR positive) and control mice (AMR culture positive after challenge) were treated with cefotaxime (CTX) antibiotic to select for mouse gut bacterial populations carrying the AMR plasmid 120 hours after exposure to the AMR-colonized mice. Fresh feces were collected and examined on ChromAgar plates containing CTX antibiotic using serial dilutions.

[0197] High levels of AMR (CTX-resistant) bacteria were detected in untreated control mice (Figure 15). In contrast, AMR bacteria were detected at very low levels only in one probiotic plasmid-treated mouse exposed to the IncM AMR plasmid group and one mouse exposed to the IncC AMR plasmid group. As PCR evidence of AMR plasmid DNA was found in all mice, this strongly supports that the probiotic plasmid protects the gut environment from the AMR plasmid.

[0198] All publications discussed and / or referenced herein are incorporated herein in their entirety.

[0199] References Agyekum,A.,Fajardo-Lubian,A.,Ai,X.,Ginn,A.N.,Zong,Z.,Guo,X.,et al.(2016).Predictability of Phenotype in Relation to Common beta-Lactam Resistance Mechanisms in Escherichia coli and Klebsiella pneumoniae.J Clin Microbiol 54,1243-50. De La Cruz,F.& Grinsted,J.(1982).Genetic and molecular characterization of Tn21,a multiple resistance transposon from R100.1.J Bacteriol 151,222-28. Espedido,B.A.,Partridge,S.R.& Iredell,J.R.(2008).bla IMP-4 in different genetic contexts in Enterobacteriaceae isolates from Australia.Antimicrob Agents Chemother 52,2984-7. Fajardo-Lubian,A.,Ben Zakour,N.L.,Agyekum,A.,Qi,Q.& Iredell,J.R.(2019).Host adaptation and convergent evolution increases antibiotic resistance without loss of virulence in a major human pathogen.PLoS Pathog 15,e1007218. Humbert,M.,Huguet,K.T.,Coulombe,F.& Burrus,V.(2019).Entry Exclusion of Conjugative Plasmids of the IncA,IncC,and Related Untyped Incompatibility Groups.J Bacteriol 201. Kamruzzaman, M., Shoma, S., Thomas, CM, Partridge, SR & Iredell, JR (2017). Plasmid interference for curing antibiotic resistance plasmids in vivo. PLoS One 12,e0172913. Matsumura, Y., Peirano, G. & Pitout, JDD (2018). Complete genome sequence of Escherichia coli J53, an azide-resistant laboratory strain used for conjugation experiments. Genome Announc 6. Murphy, KC & Campellone, KG (2003). Lambda Red-mediated recombinogenic engineering of enterohemorrhagic and enteropathogenic E. coli. BMC Mol Biol 4,11. Papagiannitsis, CC, Kutilova, I., Medvecky, M., Hrabak, J. & Dolejska, M. (2017). Characterization of the Complete Nucleotide Sequences of IncA / C. Antimicrob Agents Chemother 61.

[0200] (Additional Note) (Appendix 1) A recombinant plasmid comprising an entry inhibition system (EES) from multiple plasmid variants, said plasmid variants comprising a gene conferring a trait of interest.

[0201] (Appendix 2) 2. The recombinant plasmid of claim 1, wherein the trait of interest is an undesirable trait in a bacterial population.

[0202] (Appendix 3) 3. The recombinant plasmid of claim 2, wherein the trait of interest is antimicrobial resistance (AMR), bacterial virulence, or heavy metal resistance.

[0203] (Appendix 4) 2. The recombinant plasmid of claim 1, wherein the recombinant conjugative plasmid comprises EES from at least three plasmid variants that contain the gene conferring the trait of interest.

[0204] (Appendix 5) 5. The recombinant plasmid of any one of claims 1 to 4, wherein the EESs are from different incompatibility groups.

[0205] (Appendix 6) 5. The recombinant plasmid of any one of claims 1 to 4, wherein the EESs are from the same incompatibility group.

[0206] (Appendix 7) 7. A recombinant plasmid according to any one of appendix 1 to 6, wherein one or more of the EESs are from a plasmid variant from an incompatibility group (Inc) selected from IncF, IncI, IncA, IncC, IncL, IncM, IncX, IncP, IncN, and IncH.

[0207] (Appendix 8) 8. The recombinant plasmid of claim 7, wherein one or more of the EESs are from a plasmid variant of incompatibility group F (IncF).

[0208] (Appendix 9) an EES (traS_F variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO:1; An EES comprising a polynucleotide sequence that is at least 80% identical to the sequence set forth in SEQ ID NO:2 (traS-R100 variant), and / or An EES (traS_SLT variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO:3; 9. The recombinant plasmid of claim 8, comprising one or more of the following:

[0209] (Appendix 10) An EES (traS_F variant) comprising the polynucleotide sequence set forth in SEQ ID NO:1; An EES comprising the polynucleotide sequence set forth in SEQ ID NO:2 (traS_R100 variant), and / or EES (traS_SLT variant) comprising the polynucleotide sequence set forth in SEQ ID NO:3; 10. The recombinant plasmid of claim 8 or 9, comprising one or more of the following:

[0210] (Appendix 11) 13. A recombinant plasmid according to any one of appendix 8 to 12, comprising the traS_F variant EES, the traS_R100 variant EES, and the traS_SLT variant EES.

[0211] (Appendix 12) 11. A recombinant plasmid according to any one of appendix 1 to 10, comprising one or more EES from a plasmid variant of incompatibility group L (IncL), incompatibility group C (IncC), incompatibility group M (IncM), incompatibility group A (IncA), and any combination thereof.

[0212] (Appendix 13) An EES (excL variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO: 9; An EES (excC variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO: 10; An EES (excM variant) comprising a polynucleotide sequence that is at least 80% identical to the sequence set forth in SEQ ID NO: 11, and / or An EES (excA variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO: 12; 13. The recombinant plasmid of claim 12, comprising one or more of:

[0213] (Appendix 14) EES (excL variant) comprising the polynucleotide sequence set forth in SEQ ID NO: 9; An EES (excC variant) comprising the polynucleotide sequence set forth in SEQ ID NO: 10; An EES comprising the polynucleotide sequence set forth in SEQ ID NO: 11 (excM variant), and / or An EES (excA variant) comprising the polynucleotide sequence set forth in SEQ ID NO: 12; 14. The recombinant plasmid of claim 12 or 13, comprising one or more of:

[0214] (Appendix 15) 15. The recombinant plasmid of any one of claims 1 to 14, wherein one or more of the EESs are operably linked to a constitutive promoter, optionally wherein the constitutive promoter is selected from a promoter native to the EES or a strong integron promoter (PcS).

[0215] (Appendix 16) 15. The recombinant plasmid of any one of claims 1 to 14, wherein one or more of the EESs are operably linked to an inducible promoter, optionally wherein the inducible promoter is an L-arabinose inducible promoter.

[0216] (Appendix 17) 17. The recombinant plasmid according to any one of claims 1 to 16, wherein each EES is operably linked to a separate promoter.

[0217] (Appendix 18) 17. The recombinant plasmid according to any one of claims 1 to 16, wherein the one or more EESs are operably linked to the same promoter.

[0218] (Appendix 19) 19. The recombinant plasmid of any one of appendix 1 to 18, further comprising a plurality of plasmid replication incompatibility (Inc) control regions (Inc-control), and / or a selectable marker or gene.

[0219] (Appendix 20) the Inc regulatory region is from a plasmid variant from the Inc group selected from IncF, IncI, IncA, IncC, IncL, IncM, IncX, IncP, IncN, and IncH; the Inc regulatory region and the EES are from the same Inc group; one or more of the Inc regulatory regions is from a plasmid variant of IncF; one or more of the Inc regulatory regions are from a plasmid variant of IncA, IncC, IncL, and / or IncM; and / or the selectable marker or gene is an antibiotic resistance gene; 19. A recombinant conjugative plasmid described in Appendix 19.

[0220] (Appendix 21) A bacterial cell comprising a recombinant plasmid according to any one of claims 1 to 20.

[0221] (Appendix 22) 22. The bacterial cell of claim 21, wherein the bacterium is a probiotic bacterium.

[0222] (Appendix 23) 23. The bacterial cell of claim 22, wherein the probiotic bacteria is selected from the group including, but not limited to, Escherichia, Klebsiella, other members of the Enterobacteriaceae family, Lactobacillus, Bifidobacteria, Streptococcus, Lactococcus, Enterococcus, Propionibacterium, Faecalibacterium, Pediococcus, Ruminococcus, Megasphaera, Bacillus, and suitable members of the Pseudomonadaceae and Vibrionacecae families.

[0223] (Appendix 24) A composition comprising one or more live bacterial cells according to any one of claims 21 to 23.

[0224] (Appendix 25) 25. The composition of claim 24, wherein the live bacterial cells are lyophilized and / or formulated in a food or beverage product.

[0225] (Appendix 26) 26. A method for preventing or reducing the acquisition and / or spread of a plasmid conferring a trait of interest in a population of bacteria, said method comprising introducing into said population one or more bacterial cells according to any one of appendices 21 to 23, or one or more bacterial cells according to appendices 24 or 25.

[0226] (Appendix 27) (i) the trait of interest is antimicrobial resistance (AMR) and one or more of the bacterial cells introduced into the population comprises a recombinant conjugative plasmid according to any one of appendices 1 to 30, the recombinant conjugative plasmid comprising an entry exclusion system (EES) from multiple plasmid variants that confers AMR; or (ii) the trait of interest is bacterial virulence and one or more of the bacterial cells introduced into the population comprises a recombinant conjugative plasmid according to any one of appendices 1 to 20, comprising an entry inhibition system (EES) from multiple plasmid variants that confers bacterial virulence; 27. The method according to claim 26.

[0227] (Appendix 28) 28. The method of claim 26 or 27, wherein the population of bacteria is a population of Enterobacteriaceae, and the method comprises administering the one or more bacterial cells, or a composition comprising the one or more bacterial cells, to a subject in need of the obtaining and / or spreading.

[0228] (Appendix 29) 29. The method of claim 28, wherein the subject is a human or a non-human animal.

[0229] (Appendix 30) (i) the bacterial population is a bacterial population that colonizes a plant, and the method comprises contacting the plant or the soil in which the plant is growing with the one or more bacterial cells, or a composition comprising the one or more bacterial cells; or (ii) the bacterial population is present in an environment selected from a health care environment, a soil environment, an environment containing a water source, an environment containing wastewater, an environment containing industrial waste, an environment containing agricultural waste, an environment containing sewage, and / or an environment containing biosolids, and the method comprises introducing the one or more bacterial cells or a composition comprising the one or more bacterial cells into the environment. 28. The method according to claim 26 or 27.

[0230] (Appendix 31) 26. A food product or beverage comprising one or more bacterial cells according to any one of claims 21 to 23, or a composition according to claim 24 or 25.

[0231] (Appendix 32) 32. The food product of claim 31, wherein the food product is a dairy product.

Claims

1. A recombinant plasmid comprising an entry inhibition system (EES) from multiple plasmid variants, said plasmid variants comprising a gene conferring a trait of interest.

2. 2. The recombinant plasmid of claim 1, wherein the trait of interest is an undesirable trait in a bacterial population.

3. 3. The recombinant plasmid of claim 2, wherein the trait of interest is antimicrobial resistance (AMR), bacterial virulence, or heavy metal resistance.

4. 2. The recombinant plasmid of claim 1, wherein the recombinant conjugative plasmid comprises EES from at least three plasmid variants that contain the gene that confers the trait of interest.

5. The recombinant plasmid of any one of claims 1 to 4, wherein the EESs are from different incompatibility groups.

6. The recombinant plasmid of any one of claims 1 to 4, wherein the EESs are from the same incompatibility group.

7. 7. The recombinant plasmid of any one of claims 1 to 6, wherein one or more of the EESs are from a plasmid variant from an incompatibility group (Inc) selected from IncF, IncI, IncA, IncC, IncL, IncM, IncX, IncP, IncN, and IncH.

8. 8. The recombinant plasmid of claim 7, wherein one or more of the EESs are from a plasmid variant of incompatibility group F (IncF).

9. EES comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO:1 (traS_F variant); An EES comprising a polynucleotide sequence that is at least 80% identical to the sequence set forth in SEQ ID NO:2 (traS-R100 variant), and / or EES (traS_SLT variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO:3; 9. The recombinant plasmid of claim 8, comprising one or more of the following:

10. EES comprising the polynucleotide sequence set forth in SEQ ID NO:1 (traS_F variant); EES comprising the polynucleotide sequence set forth in SEQ ID NO:2 (traS_R100 variant), and / or EES comprising the polynucleotide sequence set forth in SEQ ID NO:3 (traS_SLT variant); 10. The recombinant plasmid of claim 8 or 9, comprising one or more of the following:

11. 13. The recombinant plasmid of claim 8, comprising the traS_F variant EES, the traS_R100 variant EES, and the traS_SLT variant EES.

12. 11. The recombinant plasmid of any one of claims 1 to 10, comprising one or more EES from a plasmid variant of incompatibility group L (IncL), incompatibility group C (IncC), incompatibility group M (IncM), incompatibility group A (IncA), and any combination thereof.

13. EES (excL variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO:9; EES (excC variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO: 10; An EES (excM variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO: 11; and / or EES (excA variant) comprising a polynucleotide sequence at least 80% identical to the sequence set forth in SEQ ID NO: 12; 13. The recombinant plasmid of claim 12, comprising one or more of:

14. EES comprising the polynucleotide sequence set forth in SEQ ID NO:9 (excL variant); EES comprising the polynucleotide sequence set forth in SEQ ID NO: 10 (excC variant); EES comprising the polynucleotide sequence set forth in SEQ ID NO: 11 (excM variant), and / or EES comprising the polynucleotide sequence set forth in SEQ ID NO: 12 (excA variant); 14. The recombinant plasmid of claim 12 or 13, comprising one or more of the following:

15. 15. The recombinant plasmid of any one of claims 1 to 14, wherein one or more of the EESs are operably linked to a constitutive promoter, optionally selected from a promoter native to the EES or a strong integron promoter (PcS).

16. 15. The recombinant plasmid of any one of claims 1 to 14, wherein one or more of the EESs are operably linked to an inducible promoter, optionally, the inducible promoter is an L-arabinose inducible promoter.

17. The recombinant plasmid of any one of claims 1 to 16, wherein each EES is operably linked to a separate promoter.

18. The recombinant plasmid of any one of claims 1 to 16, wherein the one or more EESs are operably linked to the same promoter.

19. 19. The recombinant plasmid of any one of claims 1 to 18, further comprising a plurality of plasmid replication incompatibility (Inc) control regions (Inc-control), and / or a selectable marker or gene.

20. the Inc regulatory region is from a plasmid variant from the Inc group selected from IncF, IncI, IncA, IncC, IncL, IncM, IncX, IncP, IncN, and IncH; the Inc regulatory region and the EES are from the same Inc group; one or more of the Inc regulatory regions is from a plasmid variant of IncF; one or more of the Inc regulatory regions are from a plasmid variant of IncA, IncC, IncL, and / or IncM; and / or the selectable marker or gene is an antibiotic resistance gene; 20. The recombinant conjugative plasmid of claim 19.

21. A bacterial cell comprising a recombinant plasmid according to any one of claims 1 to 20.

22. The bacterial cell of claim 21 , wherein the bacterium is a probiotic bacterium.

23. 23. The bacterial cell of claim 22, wherein the probiotic bacteria is selected from the group including, but not limited to, Escherichia, Klebsiella, other members of the Enterobacteriaceae family, Lactobacillus, Bifidobacteria, Streptococcus, Lactococcus, Enterococcus, Propionibacterium, Faecalibacterium, Pediococcus, Ruminococcus, Megasphaera, Bacillus, and suitable members of the Pseudomonadaceae and Vibrionacecae families.

24. A composition comprising one or more live bacterial cells according to any one of claims 21 to 23.

25. 25. The composition of claim 24, wherein the live bacterial cells are lyophilized and / or formulated in a food or beverage product.

26. 27. A method for preventing or reducing the acquisition and / or spread of a plasmid conferring a trait of interest in a population of bacteria, said method comprising introducing into said population one or more bacterial cells according to any one of claims 21 to 23, or a composition comprising one or more bacterial cells according to claims 24 or 25.

27. (i) the trait of interest is antimicrobial resistance (AMR) and one or more of the bacterial cells introduced into the population comprises a recombinant conjugative plasmid according to any one of claims 1 to 30, comprising an entry exclusion system (EES) from multiple plasmid variants that confers AMR; or (ii) the trait of interest is bacterial virulence and one or more of the bacterial cells introduced into the population comprises a recombinant conjugative plasmid according to any one of claims 1 to 20, comprising an entry exclusion system (EES) from multiple plasmid variants that confers bacterial virulence; 27. The method of claim 26.

28. 28. The method of claim 26 or 27, wherein the bacterial population is a population of enterobacteria, and the method comprises administering the one or more bacterial cells, or a composition comprising the one or more bacterial cells, to a subject in need of the acquisition and / or spread.

29. 29. The method of claim 28, wherein the subject is a human or a non-human animal.

30. (i) the bacterial population is a bacterial population that colonizes a plant, and the method comprises contacting the plant or the soil in which the plant is growing with the one or more bacterial cells, or a composition comprising the one or more bacterial cells; or (ii) the bacterial population is present in an environment selected from a health care environment, a soil environment, an environment comprising a water source, an environment comprising wastewater, an environment comprising industrial waste, an environment comprising agricultural waste, an environment comprising sewage, and / or an environment comprising biosolids, and the method comprises introducing the one or more bacterial cells, or a composition comprising the one or more bacterial cells, into the environment.

28. The method of claim 26 or 27.

31. 26. A food product or beverage comprising one or more bacterial cells according to any one of claims 21 to 23 or a composition according to claim 24 or 25.

32. 32. The food product of claim 31 , wherein the food product is a dairy product.

Citation Information

Patent Citations

  • Bacterial conjugation systems and their therapeutic uses

    JP2021531039A